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ABSTRACT 
Asthma is a chronic disease whose effects are controlled/ prevented using appropriate 
medication. Although benefits of asthma medication is well known, poor medication adherence 
among asthma patients has been reported. Medication non-adherence is associated to increased 
healthcare costs, unnecessary hospital utilization, readmissions and even death in few cases. The 
overarching goal of this research was to evaluate the impact of medication non-adherence on 
hospital admissions, and identify key factors that result in medication non-adherence for 
Medicaid insured asthma patients. 
To achieve these objectives, Correlation analysis, T-tests, Multivariate logistic analysis 
and odds ratios were performed. Based on results of the study, the present study did not find 
significant relationships between control medication adherence and the different types of hospital 
visits (i.e. emergency department visits, inpatient admits, and readmissions). However, patients 
with high rescue medication adherence had fewer emergency department visits (p-value=0.0004) 
and inpatient admissions (p-value=0.0303). Patients with more than 4 office visits had better 
rescue medication adherence, older and low-income patients had higher 30-day readmissions 
rate. While, male and low-income patients had emergency visits 
 
Additionally, The two types of insurance coverages (Temporary Assistance for Needy Families 
and Supplemental Security Income-Non Dual) were the only significant predictors of control 
medication adherence among the factors analyzed (with p-values =0.0001). Asthma patients with 
TANF and SSI- Non Dual coverages are less adherent to control medication adherence compared 
to other coverages. Also, control and rescue medication adherence was not significantly different 
among case managed and non-case managed asthma patients. 
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CHAPTER 1: INTRODUCTION 
1.1 Introduction 
In recent times, the healthcare industry has made great strides in the prevention and curing of 
disease through science.  Prescription medicines and advances in medical treatment are available 
to manage chronic and acute conditions. Even though the healthcare industry has been vouching 
for proper use of medication, evidence is available on the prevalence of medication non-
adherence. Multiple studies have suggested that patients with poor medication adherence 
experience poorer health outcomes and often are the most costly members for their insurance 
companies. Although asthma medications can not cure asthma they help reduce symptoms and 
prevent asthma attacks. Health outcomes of asthma patients can be improved through 
pharmacologic interventions by patient or their family and provider (Pedersen, 2011). Subpar or 
irregular medication use has been associated with hospitalizations, hospital readmissions, 
emergency department visits, office visits and unnecessary utilization of medical resources 
(Miller, 1997). Taking the right medicine at the right time in a proper way, as prescribed by the 
doctor, is very important for many chronic illnesses, such as asthma.  
According to an Asthma fact report published by Centers for disease control (CDC) in 
2013, 3,404 deaths, 439,400 hospitalizations, 1.8 million ED visits and 14.2 million office visits 
were reported for the year 2010 (Asthma facts, 2013). Hospital admissions, especially 
readmissions are costly. Medicare estimated the cost of hospital readmissions to be $17.4 billion 
annually (Jencks et al., 2009) and most of these readmissions are preventable. In an attempt to 
reduce healthcare costs and readmission rates, the hospital readmission reduction program 
(HRRP) under the Affordable Care Act penalizes hospitals with excessive readmission rates 
within 30-days of initial discharge. Therefore under this policy, hospitals and care providers are 
forced to improve patient care and reduce unplanned 30-day readmissions (Greenwald, 2007). 
This readmission program greatly impacts hospital’s financial performance and makes patient 
with chronic illnesses, such as asthma, a high risk.  
Understanding factors resulting in medication non-adherence is valuable to improve 
medication adherence behavior in patients and in turn reduce non-adherence related hospital 
readmission of asthma patients. In the literature, research concerning barriers for medication 
adherence among asthma is well documented. However, it mainly focuses on identifying risk 
factors, and very few studies attempted to look at the bigger picture i.e. determining the influence 
of medication adherence on 30-day readmission rates as well as identifying factors affecting 
medication non-adherence and appropriate intervention strategies.  
The asthma data needed for this study was collected from a healthcare insurance provider 
in Louisiana from active members with an insurance enrollment gap of 45 days or less during 
January 2015 through December 2016. Medication Possession Ratio (MPR) with variable 
duration (first and last medication fill date for each individual patient) was used to measure 
medication adherence for this study. MPR was calculated for each class of asthma medication 
i.e. Control medication adherence, Rescue medication adherence and overall MPR for both 
classes of medication for each individual patient. Variable MPR was calculated as summation of 
all days supply divided by the time between the last and first fill date plus the last days supply of 
medication MPR. Days supply of the last fill is added to estimate the expiration of supply.  
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This study is divided into two parts. The objective of the first part was to evaluate the 
impact of medication adherence on 30 day & 90 day hospital readmissions for asthma among 
Medicaid patients in Louisiana. Further, the effect of age, gender, and discontinuation of certain 
medications on medication adherence and readmissions will also be evaluated. The next part of 
the study focuses on exploring factors influencing medication adherence among asthma patients 
and proposing interventions to improve medication adherence behavior. 
1.2 Problem Statement 
Recent policy changes in healthcare, requires healthcare businesses to have a better 
understanding of factors that can reduce their cost and improve health outcomes for their 
patients. Research shows that 75% of total healthcare spending is accounted by chronic 
conditions such as heart failure, COPD, diabetes, hypertension, asthma and depression (Jack 
Meyer, 2013). Patients with chronic conditions avail more healthcare resources such as 
emergency visits, hospital admissions, special assistance and multiple expensive medications. 
Although most of the chronic conditions can be managed via proper medication regimen and life 
style changes, there is a definite gap between physician orders and patients’ compliance. 
Previous studies have shown that 10 to 50% of hospital readmissions are considered to be 
avoidable (Jencks, 2009). Therefore, in order to reduce avoidable healthcare costs, the focus 
needs to be shifted to improve patient health and reduce unnecessary utilization of resources.  
Understanding major contributors of medication non-adherence will be a useful resource in 
quality improvement and cost reduction efforts (Anika et al., 2014) and in turn reduce expensive 
hospitalizations and readmissions. 
1.3 Research Objectives 
The overarching goal of this research was to evaluate the impact of medication non-
adherence on hospital readmission, and identify key factors that result in medication non-
adherence for asthma patients. This thesis document comprises two journal papers directed 
toward medication non-adherence and hospital readmission trends for asthma patients.  
Paper 1: Empirical Study on Medication Adherence and Hospital Readmission for Medicaid 
Insured Asthma Patients- this paper focuses on evaluating the effects of medication non-
adherence on patient readmission rates for asthmatic patients. Furthermore, it identifies trends 
among asthmatic patient’s medication adherence behaviors with respect to scheduled doctor 
visits versus emergency visits (e.g. emergency department, hospitalization and readmission). 
This paper will be submitted for publication in the Journal of Allergy and Clinical Immunology.  
Paper 2: Selection Criteria for Intervention to Improve Medication Adherence for Asthma 
Patients - this paper focuses on identifying key factors and barriers of medication non-adherence 
among Medicaid insured asthma patients, evaluating the effectiveness of case management 
services and recommending effective patient selection criteria for intervention that will improve 
medication adherence rates. This paper will be submitted for publication in the International 
Journal of Health Care Quality Assurance. 
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1.4 Outline of the thesis 
This thesis follows the paper style, and entails an introduction, two journal papers, 
conclusion, future work and reference section.  
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CHAPTER 2: PAPER #1 
 
“Asthma study on medication adherence and hospital utilization among Medicaid insured 
asthma patients”, proposed submission to the Journal of Allergy and Clinical Immunology  
 
2.1 Abstract 
 
Medication adherence is an important indicator of quality in healthcare and non-adherence is 
associated with increased healthcare costs, hospitalizations, readmissions and decline in health 
outcomes. Despite the availability of medication to control and avoid adverse health situations, 
adherence to these medications among asthma patients varies between 40% and 60%, with 80% 
and above being the threshold of good medication adherence (Menckeberg et al., 2008). The aim 
of this study is to evaluate the effects of medication non-adherence on patient hospital 
readmission rates for asthmatic patients in Louisiana, according to their pharmacy records from 
their insurance company during the study period of January 2015- December 2016. Furthermore, 
the study identifies trends among asthmatic patient’s medication adherence behaviors with 
respect to scheduled doctor visits versus emergency visits (e.g. emergency department, 
hospitalization and readmission). The present study did not find significant relationships between 
control medication adherence and the different types of hospital visits (i.e. emergency 
department visits, inpatient admits, and readmissions). However, patients with high rescue 
medication adherence had fewer emergency department visits (p-value=0.0004) and inpatient 
admissions (p-value=0.0303). Patients with more than 4 office visits had better rescue 
medication adherence. Older and low-income patients had higher 30-day readmissions rates. 
Similarly, male and low-income patients had emergency visits. 
 
2.2 Introduction  
 
Non-adherence to medications is a persistent problem, in particular for patients with chronic 
conditions. Taking medications as prescribed is associated with lower healthcare expenditure, 
decline in number of hospitalizations, readmissions and deaths (Claxton, 2012). Medication 
adherence is critical for the success of pay-for-performance approach recently adopted by the 
U.S. healthcare system. This approach provides financial incentives to hospitals, physicians, and 
other health care providers for achieving optimal outcomes for patients, making readmission 
within 30 days for the same condition a main concern. Pay-for-performance has become popular 
among policy makers and private and public payers, including Medicare and Medicaid. One in 
five Medicare patients discharged from hospitals are readmitted to a hospital within 30 days of 
initial discharge (Nehi, 2012). Asthma is a common chronic disease affecting 300 million people 
across the world (Jindal, 2012) that could result in hospitalizations and readmissions. Most 
asthma hospitalizations are considered avoidable, as the symptoms can be prevented and 
controlled with the appropriate use of medications, proper asthma management at home and 
outpatient care (Mackinon, Flagstad, Peterson, & Mesch-Beatty, 1996). The objective of this 
study is to investigate the association between medication adherence and hospital readmissions 
among Medicaid insured asthma patients in Louisiana. The study evaluates the medication 
adherence and readmission rates (30 day and 90 day) among asthma patients for a 2 years period 
(January 2015- December 2016) using pharmacy and healthcare claims data provided by an 
insurance company serving Medicaid beneficiaries.  
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2.3 Literature review 
 
2.3.1 Asthma Medication and Current Treatment 
 
Medication is the primary choice for medical interventions in all chronic conditions since these 
conditions cannot be cured, but exacerbations can be prevented and controlled. This study 
focuses on one chronic condition, asthma. Asthma management focuses on avoiding triggers, 
controlling the symptoms and reducing exacerbations- the latter two can be achieved by using 
proper medications. Asthma medicines minimize the risk of severe flare-ups and help asthma 
patients in leading an active life. Medicines are prescribed depending on age, severity of asthma, 
symptoms and side effects. According to National Asthma Education and Prevention Program 
(NAEPP), asthma medications are classified as “rescue” or quick relief or short-term 
medications, and “control” or preventive or long-term medications (NAEPP, 2007).  
 
Rescue medications are often referred to as “bronchodilators” and are used in case of acute 
asthma attacks for quick relief. The effect of rescue medications lasts up to 4 to 6 hours 
(Adkinson, 2014). These medications are not recommended to be used very often due to their 
reported side effects such as muscle tremor, rapid heartbeat and restlessness (O’Byrne, 2001). 
Rescue medications are available in forms of liquids, tablets, capsules, and injections but inhalers 
are most commonly prescribed and preferred. There are three classes of rescue medications: 
 Short-acting beta- agonists (SABA): Bronchodilator used to relieve symptoms 
quickly (e.g. Albuterol) 
 Anticholinergics: Bronchodilators used with or instead of SABA (e.g. 
Ipratropium) 
 Systemic corticosteroids: Drugs used to manage flare-ups and acute asthma 
attacks (e.g. Cortisone) 
 
Rescue medications helps stop asthma attacks after they have started; whereas control 
medications are used to prevent asthma attacks from starting. Control medications reduce the 
swelling and mucus production in airways. They are used on daily basis for patients with 
persistent asthma to prevent exacerbations and inflammations. Effects of these medications last 
up to 12 hours or more (Adkinson, 2014; (Watts, 2009), and there are different classes: 
 Inhaled corticosteroids (ICS): Anti-inflammatory drugs (e.g. Budesonide) 
 Long-acting beta-agonists (LABA): Bronchodilator used to open airways (e.g. 
Severent) 
 Combination inhalers (ICS/LABA): Combination of ICS and LABA (e.g. Advair 
and Symbicort) 
 Cromolyn sodium and nedocromil: Add on controller medications or alternatives 
for inhaled steroids. 
 Leukotriene receptor antagonists (LTRAs): Anti-inflammatory drugs (e.g. 
Singulair and Zyflo) 
 Immunomodulators: Injection used for moderate to severe asthma related to 
allergies 
 Methylxanthines: Bronchodilator used to prevent symptoms in the night (e.g. 
theophylline). 
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Additional treatments also include bronchial thermoplasty and immunotherapy (Dhar & Goshal, 
2013).  
(a) Bronchial thermoplasty: The U.S. Food and drug Administration (FDA) approved 
procedure involving direct application of thermal energy to mass of smooth muscle in 
managing severe asthma (Cox et al., 2006). 
(b) Immunotherapy: Small doses of substances (to which a person is allergic to) are injected 
under the skin of an asthma patient to reduce their response to the allergens and 
symptoms overtime (Joint Task force, 2011). 
 
A wide majority of asthma patients are not be able to use bronchial thermoplasty as it is an 
expensive procedure and is not covered under government insurance. In addition, there is a lot of 
controversy surrounding immunotherapy and using medication to manage exacerbations and 
prevent attacks is unanimously agreed upon in the literature.  
 
Asthma medications prescribed vary across ages. Adults are treated with independent medication 
(monotherapy), while combination medications (adjunctive medication) are often prescribed for 
children and adolescents (NAEPP, 2007). Although, monotherapy with control medications is 
most effective in reducing airway inflammations and improving lung function, LABA 
monotherapy is not recommended for long-term control of asthma due to increased risk of 
asthma deaths (Nelson, 2006). There is conflicting research over which controller medication 
should be preferred. The National Asthma Education and Prevention Program (NAEPP) 
recommends ICS over other control medication due to reduced exacerbations, fewer 
hospitalizations and its superior anti-inflammatory quality compared to other controller 
medication, including leukotriene receptor antagonists (LTRAs) (NAEPP, 2007; Strunk, 2006; 
O’Byrne, 2006). Although ICS is referred to as the cornerstone for controlling asthma symptoms, 
concerns have been raised due to perceived adverse effects experienced by few people. A 
retrospective data analysis on outcomes associated with initiation of different controller therapies 
among Medicaid asthma population found that LTRAs are more effective in controlling asthma 
over ICS (Balakrishnan, 2005). As a part of treatment, asthma patients that cannot be controlled 
by using only one control medication are often prescribed combination medication, also known 
as adjunctive therapy. Three of the most common choices of combination medication with ICS 
are ICS + long-acting beta-agonists (LABA), ICS + LTRA, and ICS + theophylline. ICS + 
LABA combination is widely preferred over other combinations among older people and 
additional research is required on its effects on children 5-11 years (Watts, 2009). The British 
Thoracic Society/ Scottish Intercollegiate Guideline Network (BTS/SIGN) recommended 
prescribing ICS in combination with LABA in a single inhaler, to avoid adverse effects with 
LABA monotherapy (SIGN, 2012). Complete treatment for asthma includes combination of 
long-term medications such as inhaled corticosteroids (ICS) and use of short-acting beta- 
agonists in case of sudden attacks (Mayo Clinic, 2012). In order to find association between 
medications and related chances of readmissions, all the drug classes of rescue and controller 
medication taken by asthma patients (with an inpatient admission) during the study period are 
considered in this study.  
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2.3.2 Asthma Management Guidelines 
 
Certain guidelines have been published in order to improve patient health outcomes and 
encourage involvement of patients through education and demonstration of the benefits on 
following a plan. The National Heart, Lung and Blood Institute (NHLBI) established strategies 
through the National Asthma Education and Prevention Program (NAEPP) for diagnosis and 
management of asthma in 1991. The practice of these clinical guidelines resulted in fewer 
hospitalizations and deaths associated to asthma, as reported on the 2007 Expert Panel Report 3 
(EPR-3) (NAEPP, 2007). EPR-3 is a complete report of the best clinical practices in asthma care 
focusing on reducing impairment and likelihood of future asthma attacks. The report focuses on 
four components of care: a) Assessment and monitoring, b) Patient education, c) Control 
environmental factors and comorbid conditions, and d) Medications. Importance of using an 
asthma action plan was highlighted in this report. An asthma action plan is developed by the 
doctor and helps patient get involved in taking responsibility and self-managing their or their 
children’s illness. It is a plan for how and when a medication needs to be taken.  
Another asthma treatment strategy that was the basis for many national guidelines is the Global 
Initiative for Asthma (GINA). GINA was initiated with a goal of providing information about 
asthma management and translating scientific evidence research into improved care. GINA has 
published and annually updated its global strategy for asthma management and prevention for 
the past 20 years. This strategy emphasizes the patient and doctor partnership as being crucial for 
satisfactory health outcomes. While the issue of 2012 placed significant importance on having a 
written asthma action plan for self-management of asthma, the 2015 issue recommended targeted 
treatment and evidence-based approach to implement interventions effectively. A retrospective 
research containing data from three clinical studies, based on parameters derived from GINA 
guidelines, showed a positive relationship between the guidelines and improved quality of life 
(Bateman, Frith, & Braunstein, 2002). 
Both NAEPP and GINA guidelines are a step-wise approach to control asthma. NAEPP has a 6-
step approach and GINA has 5-Step approach of medications to be used, asthma education and 
management of comorbidities. According to both guidelines, low-dose ICS are considered first 
for controlling asthma across adults and older people. SABAs are prescribed across all age 
groups and severities for quick relief to bronchospasm or exercise induced asthma. Frequent 
need for SABA or LABA is an indication for need of increased care, medical attention and 
therapy (NAEPP, 2007).  
2.3.3 Medication Adherence 
Approximately 117 million people in the United States live with at least one of the 10 common 
chronic conditions (i.e. hypertension, coronary heart disease, stroke, diabetes, cancer, arthritis, 
hepatitis, weak or failing kidneys, current asthma, or chronic obstructive pulmonary disease). 
Nearly half of all the adults have at least one illness that requires prescribed medication (Ward at 
el., 2012) and 1 in 12 people were reported to have asthma in the year 2009 (CDC, 2011).  
A person is said to be ‘adherent’ when they take correct doses of medication at times prescribed 
by a physician (Osterberg & Blaschke, 2005). Medication adherence is an umbrella term for 
compliance and persistence. It is often defined as “the extent to which a patient’s behavior 
corresponds with recommendations from a health care provider” (WHO, 2003). In terms of 
medication fills, adherence refers to filling out a medication prescription at the prescribed 
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frequency. Importance of medication adherence and its positive association with improved 
healthcare outcomes has been well documented in the literature. A study on patients with 
cardiovascular diseases found that high adherence to antihypertensive medications were 
associated with higher control of blood pressure compared to low or medium adherence 
(Krousel-Wood et al., 2015). One asthma study conducted in Canada looked at the effect of 
regular use of inhaled corticosteroids on hospitalizations, and found an overall reduction in 
hospitalization rate due to regular use of asthma medication (Suissa, 2002). Medication 
adherence is alarmingly lower among chronically ill patients compared to patients with acute 
conditions (Cramer, 2003; Jackevicius, 2002). Therefore, different measures are being taken by 
health care providers to increase medication adherence and avoid adverse situations, including: 
using electronic devices set up with reminders, follow-up telephone calls, case management and 
other healthcare services provided for educating patients on positive effects of medication 
adherence, robust discharge instructions and primary care provider’s (PCP) emphasis on 
medication (Bradley et al., 2012). 
2.3.4 Medication Non-adherence 
The practice of delaying or entirely failing to fill prescriptions, and taking them as per the 
recommendations of a physician is called non-adherence. Approximately one-half of patients in 
the United States do not take their medications as prescribed (WHO, 2003). Non-adherence 
could be intentional or unintentional and might occur during different stages of their treatment 
(Vriijens, 2012). Typically, physician prescribes the minimum doses of medication required to 
control asthma based on patient’s condition. Inconsistency in adhering to these medications 
might cause exacerbations and mislead physicians from identifying the actual reasons for the loss 
of treatment effects. This often results in unnecessary increase of dosage strength or change of 
medications (Creer & Bender, 1995). Thus, it’s critical to have a good understanding of the 
reasons and magnitude of medication non-adherence, in particular for patients with chronic 
diseases such as asthma.  
Recent estimation shows that medication non-adherence is attributed to $100-$300 billions of 
avoidable costs in the U.S. annually (IMS, 2013). The cost per non-adherent asthma patient per 
year ranged from $321 for those who were prescribed ICS monotherapy to $741 for those who 
were prescribed a combination of ICS and leukotriene receptor antagonists (Tan et al., 2009). 
Medication non-adherence not only affects the patient, it also has severe economic impact and is 
a major cause of concern for healthcare providers, organizations and payers alike (Hugtenburg J. 
G., Timmers L., Elders P. J., Vervloet M., & L, 2013). Non-adherence to medication has been 
related to reemergence of tuberculosis (Bloomm & Murray, 1992), higher viral loads in children 
with HIV/ AIDS (Martin et al., 2007), lower quality of life among adolescents receiving liver 
transplant (Fredericks et al., 2008), and higher disease-related costs and hospitalizations among 
patients with diabetes, hypertension, congestive heart failure and hypercholesterolemia (Sokol, 
McGuigan, Verbrugge, & Epstein, 2005). In particular for asthma patients, medication non-
adherence has become an area of active interest and poor adherence has been associated to 
mortality, increased direct and indirect costs, additional healthcare resource utilization, reduced 
quality of life and increased asthma symptoms (Bender, 2004; Harrison, 2003; Horne, 2006; 
(Engelkes, Janssens, de Jongste, Sturkenboom, & Verhamme, 2015).  
 
9 
 
2.3.5 Non-Adherence to Asthma Medications 
Despite of the known benefits of using control medications on a daily basis, low adherence rates 
have repeatedly been reported across studies, with ICS adherence ranging from 40% to 60% 
(Rand et al., 1995; Breekveldt, 2004). A study on asthma medication adherence and beliefs 
conducted in Sweden showed that the mean adherence value for filled prescriptions of general 
asthma medications was about 68% and although adherence to combination inhalers was higher 
compared to single inhaled corticosteroids; overall adherence to asthma medication was low 
(Axelsson, 2015). A study found that filling oral steroids prescriptions among children within 7 
days of discharge was 56% (Cooper & Hickson, 2001), and a children’s study in Canada 
evaluated the effect of filling inhaled corticosteroids within 3 months of discharge (Blais et al., 
1998). Another observational study of 56,168 in U.S., measured asthma controller medication 
adherence using pharmacy refill data and found that non-adherence was associated with higher 
asthma medical costs (Tan, 2009). The variable nature of symptoms in asthma (with periods of 
no attacks) often encourage non-adherent behavior and overtime leads to unexpected asthma 
attacks.  Non-adherence to asthma medications among children can cause excessive wheezing 
and variability in pulmonary function, limiting daily activities (Bauman, Sallis, Dzewaltowski, & 
Owen, 2002), results in exacerbations, deterioration of health, need for excessive urgent care, 
hospitalizations and death in some cases. 
2.3.6 Medication Adherence Measurement 
In order to control their illnesses, patients with chronic conditions take necessary medications 
throughout their life. Therefore tracking or measuring medication adherence among chronically 
ill yields better results compared to patients with acute illnesses. Currently, there is no gold 
standard for measuring medication adherence. Selection of an appropriate method depends on 
various factors such as the definition of adherence used, resources available, characteristics being 
evaluated, patient population, time assessment, and ethical/ legal considerations in contacting or 
interviewing the patient (Banfield, 2015). Medication adherence measures can be divided into 
two categories: subjective and objective measures. 
2.3.6.1 Subjective Measures of Medication Adherence: 
Self-reporting and self-assessment of medication adherence with surveys, questionnaires, and 
patient diaries, where patients or their family members (on behalf of children) record daily 
medication intake patterns are subjective measures of adherence (Elliott, 2006; Rand & Wise, 
1994). Many measurement scales and questionnaires, such as Morisky’s medication adherence 
scale (MMAS), Medication adherence rating scale (MARS), and Beliefs about medicines 
questionnaire (BMQ) have been developed and validated in the literature. In addition, some 
scales are developed to measure medication adherence among specific conditions. Medication 
adherence rating scale for asthma (MARSA), is a scale used in clinical practice setting to 
evaluate medication taking behaviors and attitudes among asthma patients and ASK20 is a self-
reporting tool used to measure and identify barriers for medication adherence among asthma and 
COPD patients. Although, subjective methods are cost-effective, they are unreliable and increase 
the complexity of research, Patient recall bias issues and possible “Hawthorne effect” i.e. 
increase in patient’s medication adherence because of their knowledge of being observed might 
produce dubious results.   
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2.3.6.2 Objective measures of medication adherence: 
Objective measures documented in the literature includes: 
 Biological assays: Bodily fluids such as serum, urine, blood or saliva is tested to detect 
traces of medication. Positive results for the test/ finding traces of medication is not an 
indication of adherence, it only confirms that medication was taken before the test. This 
method is invasive and gives consistent results only for certain drugs (e.g. theophylline 
and cycloporism). 
 Electronic monitoring devices: Electronic devices equipped with chips are installed in 
with inhalers or oral medications to record the time, frequency and doses of medication 
taken by the patient. Although this method is widely used, it has been equally criticized 
as the devices are expensive, need training to use and patients were found to deliberately 
use the device several times shortly before their doctor visits. 
 Pill counts and canister weights: Pill counts is a simple method where medication 
adherence is calculated by counting number of remaining medication and comparing it 
with units of medication issued. Weighing the canister or device and calculating the 
change in weight is another similar method. These methods are cost effective and simple, 
but might overestimate patient’s medication use; since pills can be disposed and inhalers 
could be emptied prior to doctor visit. 
 Pharmacy records: Pharmacy records provide patient’s medication and refill information. 
It is a simpler way of collecting medication related information such as drug name, dose, 
how many days’ worth of medication was filled by the patient, prescribing doctor and 
filling patterns of patient’s (by identifying if the patient was/ was not in possession of 
medication or if there were gaps in filling medications over the study period) for target 
population or large number of patients at once. Pharmacy information can be obtained 
from pharmacy claims data maintained by pharmacies, Insurance and healthcare 
providers. Reliability and validity of prescription claims data has been examined by 
numerous researchers in the United States This method is cost effective, noninvasive, 
simpler and proven to be efficient. However, refill behaviors do not guarantee that 
patients are actually taking the medication as prescribed. Various methods of calculating 
medication adherence using pharmacy claims records are available. This method requires 
data set to be valid, complete and accurate, patients continuous eligibility during the 
study is required along with information on changes in insurance plans and any additional 
treatment services available to the patients. A number of calculations are available in 
literature to report the rate of medication adherence among chronically ill patients. Some 
of the most commonly used calculations include Medication possession ratio (MPR), 
Cumulative medication gap (CMG) and Proportion of days covered (PDC).  
2.3.7 Medication Possession Ratio (MPR) 
 MPR is calculated as the sum of the days’ supply obtained during the study period divided by 
the total number of days in this time period plus the last fills days supply. It has been a go-to 
method to calculate medication adherence using claims data in the past. MPR measures 
adherence by assessing medication availability and determining skipped or discontinued 
medications (Md Redzuan, Lee, & Mohamed Shah, 2014). MPR is used in the literature to 
measured variable or fixed periods and they are called variable MPR (VMPR) and Fixed MPR 
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(FMPR), respectively. The main difference in the measurement of MPR is in calculating the 
denominator. The denominator of VMPR varies for each individual depending on their first and 
last fill date while the denominator of FMR is fixed for all study subjects i.e., the number of days 
in the study period (e.g. 1 year study period =365 days). Both methods of measurements are 
quite popular but the difference in calculating them complicates comparisons across studies 
(Kozma, Dickson, Phillips, & Meletiche, 2013). 
FMPR =  
Sum of the days supply for all claims during the study period
No. of days in study period
 x 100 
Equation 1. Fixed Medication Possession Ratio formula 
VMPR =  
Sum of the days supply for all claims during the study period
Elasped days (inclusive of last prescription)
 x 100 
Equation 2. Variable Medication Possession Ratio formula 
MPR approach to adherence measurement has a few drawbacks, such overestimating medication 
adherence as it does not address overuse that occurs when patients buy early refills of their 
medication causing an overlap and also inflation in the resulting value (Martin et al., 2009). 
However, MPR is a widely used and accepted method to measure medication adherence in the 
literature and in practice for various illnesses (Patel et al., 2010; Duncan, 2016). Several asthma 
studies evaluated medication adherence using MPR. MPR with variable denominator is the 
selected method for calculating medication adherence of asthma patients in this study. Various 
researchers have considered patients with MPR lower than 80% as non-adherent and more than 
80% are to be adherent to medication (Briesacher, 2009).  
2.3.8 Hospital Readmissions 
Hospital readmissions are defined as multiple hospital stays by the same patient within a 
specified time for reason same as related or unrelated to the index admission. Readmissions may 
occur due to multiple unexplainable reasons and can be separated by days, weeks, months or 
years (Stone &Hoffman, 2010). American Hospital Association (AHA) created a framework 
dividing readmissions into 4 types: “(a) planned readmission related to the original admission, 
such as placement of ventricular assist device following a heart attack; (b) planned readmission 
unrelated to the original admission, such as readmission for a removal of lung tumor discovered 
during an admission for heart attack; (c) an unplanned readmission unrelated to the original 
admission, such as readmission for a fracture caused by accident following an initial stay of 
pneumonia; (d) an unplanned readmission related to the initial admission, such as a surgical site 
infection or adverse reaction to a medication” (AHA, 2009). Planned readmissions are not a 
cause of concern, they are a part of treatment such as surgery follow up or rehabilitation and 
agreed upon by the provider and the patient. Unplanned readmissions related to index admission, 
on the other hand accounts to preventable costs, unnecessary resource utilization, patient 
dissatisfaction and stress to the family (Jencks, 2009). All hospital readmissions might not be 
preventable, many of them could be avoided by providing better care during treatment, and while 
transitioning from inpatient stay. 
According to a study by University HealthSystem Consortium, most readmissions occur within 7 
days of discharge (Arnold, Buys, & Fullas, 2015). Readmissions occurring shortly after hospital 
discharge are crucial. They might be a sign of insufficient discharge instructions, 
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miscommunication, physician’s inexperience, or patient’s non-adherence to discharge 
instructions. There is no a single timeframe for defining hospital readmissions in the literature. 
Studies examined readmissions within 15, 30, 60, 90 days or even a year following the discharge 
from a hospital (Stone &Hoffman, 2010). This study will focus on the 30 day readmission, given 
its criticality in regards to the pay-for-performance approach recently adopted by the U.S. 
healthcare system (MedPAC, 2007; CMS, 2012).  
In 2007, 17.6% percent of hospital admissions resulted in 30-day readmissions, accounting to 
$15 billion in Medicare spending. Medicare Payment Advisory Committee (MedPAC) reported 
that 76% of the readmission could have been avoided. Preventable inpatient spending costs 
owing to readmissions increased from $15 billion (in 2007) to $17.5 billion by 2010 Medicare 
claims (MedPAC, 2007; CMS, 2012). To address this issue and hold hospitals accountable for 
high readmissions, Congress and the Centers for Medicare and Medicaid Services (CMS) 
established the Affordable Care Act and created a Readmission Reduction Program in the year 
2012. Hospitals with excessive readmissions were penalized with one percent reduction in 
payments for heart attack, heart failure and pneumonia and the penalty was supposed to increase 
to three percent reductions extending to COPD, asthma and select cardiovascular procedures by 
the year 2015 (Axon, 2011). As a result, hospitals and care providers were forced to improve 
inpatient care, discharge planning coordination, and transitional care from hospital to home 
(Greenwald, 2007).  Although direct cost of asthma was reported to be $2.2 billion annually with 
about 347,000 hospital admissions in the year 2013, limited studies examined 30-day 
readmissions among asthma patients, especially among adults (Hasegawa, Gibo, Tsugawa, 
Shimada, & Camargo Jr, 2016). Hospital readmissions, especially 30-day readmissions are 
considered as indicator of quality. It is used as a pay per performance measure by affordable care 
act. Therefore, 30-day readmission of asthma patients across all ages will be evaluated in this 
study. Asthma studies in the literature also look at 90-day readmission rates while formulating 
interventions. A childhood asthma study, which analyzed inpatient hospitalization, outpatient 
and prescription claims records to identify patients who filled asthma discharge medication 
(short acting agonist, oral corticosteroid, or inhaled corticosteroid), within 3 days of discharge 
from a facility found that filling beta agonists and inhaled steroids was associated with lesser 
hospital readmissions (i.e. 90-days) (Kenyon et al., 2015). In addition, the 90-day readmission 
will also be analyzed.  
2.3.9 Factors Affecting Readmission 
Chronic conditions account for many hospitalizations and readmissions due to their persistent 
illness. Chronic illnesses require more resources, budget, attention and specialized services (such 
as disease management, case management, etc.) for an extended period (WHO, 2002a). 
Therefore, readmission’s role as a quality measure has increased during the past decade and 
recent studies all over the world examined factors that contribute to patient’s readmission.  
A study on childhood asthma based in Auckland, New Zealand found that patient’s age, gender, 
number of previous admissions, and severity of the condition were related to readmission during 
a 6 month period after discharge (Mitchell, Bland, & Thompson, 1994). Few other studies found 
comorbidity, length of stay, lack of documented patient or family education, insurance status, 
and marital status are patient-level factors affecting 30-day readmissions (Holloway, Medendorp, 
& Bromberg, 1990; Marcantonio et al., 1999). Gender, race, insufficient discharge planning, 
drug management and polypharmacy (e.g. use of five or more drugs), have been identified as 
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contributory factors with the highest risk of readmission (Kansagara et al., 2011, Viktil et al., 
2007;Wong et al., 2011). This goes to show that reasons for readmission are varied and hence 
not all the cases of readmission can be avoided in one specific way.  
2.3.10 Link between Readmission and Non-Adherence 
Hospital readmissions are known for being indicators of inadequate quality and key contributors 
to healthcare costs in the U.S. and around the world. Although many programs have been 
implemented to address increasing readmissions and their concurrent healthcare costs, more than 
1,400 hospitals were penalized for high readmissions rates in 2012, resulting to costs more than 
$280 million (Krauskopf et al., 2013). CMS uses data from three full years to calculate each 
hospital’s readmission rate. Therefore, data from the three years, June 2008 to July 2011 was 
used for 2013 calculations penalizing 64% of hospitals for diagnosis of heart attack, heart failure 
and pneumonia. Similarly, June 2009-July 2012 hospital data was used for calculations in 2014 
with 66% of hospitals being penalized for diagnosis of heart attack, heart failure and pneumonia. 
COPD, Hip or knee replacement were added to the list in 2015 for data from the years 2010 to 
July 2013. 78% of hospitals were penalized in the year. June 2012-July 2015 data were used to 
calculate penalties for the year 2016 owing to similar penalty as the year before i.e. 78% 
(Boccuti, 2015).  
CMS estimated that 11% of hospital readmissions occur due to medication non-adherence and 
the resulting costs are estimated to be $100-$289 billion annually (Osterberg & Blaschke, 2005). 
A study reported that hospitalizations, readmissions and even death rate were low among patients 
that are medication adherent and the risk of these hospitalizations and readmissions among non-
adherent patients was 5.4 times high among hypertension patients, 2.8 times high among 
dyslipidemia and 1.5 times high among patients with heart diseases (Gwadry-Sridhar et al. 
2009). A pediatric asthma study aimed at evaluating factors associated with readmission 
conducted a survey regarding asthma knowledge, beliefs, and medication adherence. The study 
demonstrated the need to target medication adherence in order to reduce inpatient readmissions 
(Auger, Kahn, Davis, & Simmons, 2015). Another study at a university hospital during an 11 
month period found that one-third of hospital admissions due to adverse drug events were 
medication non-adherence related (McDonnell & Jacobs, 2002). A retrospective cohort analysis 
from 12 geographically diverse states on relationship between asthma prescription filling 
patterns and hospital readmission rates among patients discharged from an inpatient facility 
found that filling of all of three recommended mediations (beta agonists, oral steroids and 
inhaled steroids) following discharge was associated with lowest risk of hospital readmission 
within 14 days and a statistically significant reduction in readmissions between 15 and 90 days 
(Kenyon et al., 2015). One study based in Brazil, assessing the effect of free asthma medications 
on hospital admissions showed that the free asthma medications provided by the Brazilian health 
system significantly decreased asthma hospitalization rates over a three year period (Comaru, 
Pitrez, Friedrich, Silveira, & Pinto, 2016). Among few studies that examined association 
between readmissions and specific asthma medications, Saratsafavi et al evaluated controller 
medication, reliever medications associated with different inhaled controller treatments as an add 
on to systemic corticosteroids, and readmission rate over a period of one year following 
discharge among asthma patients (ages 12-25). Taking inhaler medication early after discharge 
was associated with reduced readmissions and combination therapy seems to be as effective as 
inhaler medication in reducing readmissions and increasing long-term adherence (Sadatsafavi, 
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Lynd, De Vera, Zafari, & FitzGerald, 2015). A similar study regarding recurrence risk after an 
ED visit or hospitalization and delay in filling asthma controller medication reported increase in 
asthma related- ED visits or IP stay when there was a delay in initiation of controller medication 
(Sadatsafavi et al., 2015). Treatment with Budesonide inhalation suspension during the first 30 
days after inpatient stay and emergency department (ED) visits reduced asthma readmissions or 
ED visits. Asthma medication adherence has been associated with reduced exacerbations and 
hospitalizations (Camargo, Ramachandran, Ryskina, Lewis, & Legorreta, 2007). Thus, there is 
plenty of evidence in the literature on the association between medication adherence and hospital 
readmissions. This paper aims at finding the relationship between medication adherence and 30 
day readmissions among asthma patients under Medicaid. All classes of asthma medication will 
be examined to map the medication taking behavior among asthma patients. 
2.3.11 Current Practices Aimed At Reducing Readmissions 
A systematic review and meta-analysis aimed at examining the difference in medication 
adherence and readmissions between patients who received usual care and an intervention group 
found that, the intervention group (patients who received education, self-management and 
medication adherence strategies from trained nurses) had lower likelihood of readmission 
compared to control subjects (Hyrkas & Wiggins, 2014). Therefore, a number of programs have 
been designed to address transitional care needs for patients. Some of the current practices for 
readmissions and care transitions include “Project RED”, “Care Transitions Program”, “Project 
BOOST”, and “Medicare Demonstrations: Details For Community-Based Care Transition 
Program”. Project RED, is short for Project Re-Engineered Discharge developed by a research 
group at Boston University Medical Center. The group develops and tests strategies that improve 
hospital discharge process, promote safety and reduce readmission rates. RED, consists of 11 
components that have been successful in reducing readmissions. This project has demonstrated 
reduction in ED visits and readmissions within 30 days of discharge by approximately 30% (Jack 
et al., 2009).  Care Transition Program is a four week program aimed to improve patient’s 
transition from hospital to home. As a part of this program, a Transition Coach educates patients 
on self-management using specific tools to reduce readmissions among high-risk Medicare 
beneficiaries (CMS, 2007). Project BOOST, stands for Project “Better Outcomes for Older 
Adults through Safe Transitions”. This is a care initiate by Society of Hospital Medicine to 
improve transitional care among patients. A study to determine the effect of project BOOST on 
rehospitalizations and length of stay found that participation in the project appeared to be 
associated with decrease in readmission rates. The Community- Based Care Transitions Program 
(CCTP) is a program by U.S. Department of Health & Human Services, Centers for Medicare & 
Medicaid Services. It aims at reducing hospital readmissions, improving quality of care and 
document measurable savings to the Medicare program (CMS fact sheet).  
2.4 Research Methodology 
The general purpose of this study is to evaluate the effects of medication non-adherence on 
patient readmission rates for asthmatic patients. Furthermore, identifies trends among asthmatic 
patient’s medication adherence behaviors with respect to scheduled doctor visits versus 
emergency visits (e.g. emergency department, hospitalization and readmission). 
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2.4.1 Study setting 
Data for this study was sourced from a healthcare insurance provider based in Baton Rouge. The 
company provides health coverage to Medicaid or LaCHIP qualified people through state’s 
Healthy Louisiana program and links Medicaid recipients to primary care providers, pharmacies 
and case managers. Institutional Review Board at Louisiana State University reviewed and 
approved the study. 
2.4.2 Study population 
The study population consists of Medicaid patients of all ages with primary or secondary 
diagnosis of asthma and insured (with 0 or maximum 45 day enrollment gap from insurance) 
during January 1, 2015 to December 31, 2016. International Classification of Diseases, ninth 
revision code (ICD 9 codes) 493.XX and tenth revision code (ICD 10 codes) J45.XX, and the list 
of asthma medications with 9-digit National Drug Codes (NDC) within each asthma drug class 
(Control and rescue medications) were used to identify members with asthma. Patients were 
eligible for study inclusion if they met the following criteria: asthma patients admitted at least 
once to a hospitals (e.g. inpatient facility) in Louisiana for reason related to asthma; if they had 
two or more pharmacy claim for asthma control medication; if they were continuously eligible 
and enrolled in health coverage during the study period. Patients who died during the study 
period or were discharged to other facility from the hospital during their initial admission, had 
missing or invalid claims data, and medical or pharmacy claims for reasons other than or not 
related to asthma were excluded from the study. In order to compare the readmission rates an 
inpatient admissions data set was collected from a random sample of 1000 non-asthmatic 
members to be used as the non-asthmatic group.  
2.4.3 Data Source 
The insurance company’s databases, MicroStrategy and data warehouse (EDW), were used to 
gather the required data for the years 2015 and 2016. These databases capture patient level 
clinical utilization, expenditures, and admissions across inpatient, outpatient, and emergency 
department, prescription drugs filled, and enrollment into healthcare services (i.e. case 
management, disease management or other care services from within the plan). The databases 
include present and past members, and dependents insured under them. Data was available 
separately for each admits/ visits. Therefore, separate CSV files were gathered from different 
reports and linked to the patient through their Medicaid ID, initially. Health Insurance Portability 
and Accountability Act of 1996 (HIPPA) policies and guidelines were followed, and all the data 
was de-identified before data analysis.  
2.4.4 Data collection 
Data was collected from different databases called MicroStrategy and data warehouse (EDW) 
used by the insurance company. Separate reports on member data, emergency department data, 
inpatient stay and prescription medication data was collected. All the reports are linked to one 
another through member ID numbers. Figure 1 shows a schematic representation of the data 
points available in each of the reports retrieved from the database. 
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Figure 1. Schematic of data files provided by the healthcare provider 
2.4.5 Measurement of Hospital Readmissions  
30-day and 90-day readmissions were calculated from data available in the insurance claims’ 
records. Readmissions were calculated by counting days between index discharge and 
subsequent admission into the hospital and if this value fell between within 30 days and 90 days, 
it was considered as 30 or 90-day readmission. Transfer from one facility to other facility is not 
considered as hospital readmission. If the patient is discharged from the transferred facility to 
home and is admitted back into a hospital within 30 or 90 days, then it is considered as a 
readmission. 
2.4.6 Measurement of medication fills  
Pharmacy claims for the following asthma medications during the study period will be used to 
calculate the medication adherence of patients for the two types of medications- Type I- Rescue 
Medication: (1) short-acting beta agonists; (2) oral corticosteroids/ systemic corticosteroids; and 
Type II- Control Medication: (1) inhaled corticosteroids or a combination inhaled steroid and 
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long acting beta agonist; (2) Long-acting beta-agonists; (3) Leukotriene receptor antagonists; (4) 
Immunomodulators; (5) Cromolyn sodium and nedocromil; (6) and Methylxanthines. 
Medication Possession ratio (MPR) 
Control medications are the preferred medication for long-term management of asthma 
symptoms, while rescue medications are only used as per need during an asthma attack event. 
Studying Control medication adherence on patients with chronic disease like asthma is critical 
for better healthcare outcomes. MPR was calculated for control medication and rescue 
medications separately for each patient. 
 
MPR =  
Total number of days covered
Last fill date − first fill date + days supply of last fill
 x 100 
 
The above equation, was used to calculate medication adherence in this study.  First, a data file 
containing the variables such as patient ID number, National Drug Code (NDC) for drugs, date 
of prescription claim, days of supply for prescription claim, and region identifier needed to 
calculate MPR for all patients in the study was created and then the equation for calculating 
MPR, was followed. Numerator of the formula is the sum of all the days supply for the study 
period (2 years for this study) divided by the number of days elapsed (last fill date-  first fill date 
for each individual) plus days supply of last fill . 
SAS 9.4 version and excel were be used to calculate MPR. 
2.4.7 Statistical Analysis 
The overarching purpose of this study is to evaluate the effects of medication non-adherence on 
hospital visit rates for asthma patients. Some of the research questions explored in this study 
include:  
1. What is the impact of asthma patients’ prescription non-adherence (fail to refill in this 
context) on their 30-day and 90-day hospital readmission rate?  
2. Are the readmission rates for asthma patients the same as readmissions for patients 
without asthma illness (non-asthmatic group)?  
3. At the beginning of an asthma treatment, patients are scheduled to visit their doctors 
every 2 to 6 weeks and a comprehensive asthma action plan is developed to manage care. 
Once the asthma is controlled they can be scheduled to meet the doctors monthly to twice 
a year depending on their health and signs of symptoms (NHLBI, 2014). Therefore one of 
the questions was: Are 4 visits for the 2 year study period associated to higher levels of 
adherence? 
4. What is the effect of patients’ demographics on medication adherence and readmission?  
The proposition of this study is that prescription non-adherence negatively impacts the 
readmission rates on hospitals. In order to better understand the relationship between medication 
adherence and different types of patient-doctor interaction including office visits and emergency 
visits (i.e. emergency department visits, inpatient stay and hospital readmission rates), the 
following hypothesis will be tested: 
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o H1: Asthmatic patients with lower level of medication adherence, as measured by 
Medication Possession Ratio (MPR), have more emergency visits, including (emergency 
department visits, inpatient stay and hospital readmission at various intervals i.e. 30-day 
and 90-day).  
o H2: Asthmatic patients that attend at least 4 scheduled office visits have higher levels of 
medication adherence. 
o H3: Patients prescription adherence and emergency visit rates will differ by demographic 
groups (age, gender and income level). 
o H4: Readmission rates of asthma patients will be significantly different from readmission 
rates of non-asthmatic group. 
2.4.8 Data Analysis 
SAS 9.4 was used for data analysis 
1. Descriptive analysis was conducted on the sample to summarize the data collected for the 
study. This includes age, gender, income level, and insurance distribution of the study 
sample.   
2. In order to address H1, a correlation analysis was performed to discover the relationship and 
direction of relationship between office visits, emergency visits and prescription non-
adherence of asthma patients (control medication and overall medication). 
3. In order to address H2, a t-test was performed to see if patients with at least 4 scheduled 
office visits have higher levels of medication adherence. 
4. In order to address H3, a multiple regression analysis was performed to explore the 
relationship between prescription adherence and emergency visits with demographics (age, 
gender and income level). 
5. In order to address H4, a t-test as well as odds ratio was performed to assess whether the 
means of the two groups are statistically different from each other. This analysis was 
conducted to understand if readmissions characteristics are similar among asthma patients 
and the non-asthmatic group. Lessons learned from this evaluation are discussed and used to 
propose effective asthma management guidelines to increase medication adherence. 
2.5 Results: 
2.5.1 Descriptive Analysis 
(a). Sample description of asthma patients (n=687) 
Out of the 2085 asthma patients with continuous insurance eligibility for the two-year study 
period (January 2015 to December 2016), 687 patients fulfilled the inclusion criteria. A summary 
of descriptive statistics for the study population (687 patients) is shown in the tables (2.1- 2.4) 
below. The average age was found to be 20 years, with the youngest patient being 1 year old and 
the oldest being 65 years old. Most patients (65%, 449) are considered minors, under the age of 
18. Approximately 56% of the patients are females (n=384) and 44% are male (n=303), as shown 
in Table 2.2. Table 2.3 is related to income distribution shows that 70% of the patients received 
median household income of $25,000 to $50,000. From Table 2.4, it is noted that asthma 
population for this study are covered under 6 insurance coverages: Temporary assistance for 
needy families (TANF) covers 60% of the patients, Medicaid Expansion covers 22% of the 
patients, Supplemental security income Non-dual (SSI Non-Dual) covers approximately 12%, 
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Foster care covers 2%, Behavioral health covers 1% and Children’s Health Insurance Program 
(CHIP) covers 0.29% of the patients. Eligibility criteria for each of the coverages is different and 
all of them provide low-cost healthcare coverage to Americans falling under one or more of the 
following criteria: people with low income, children, foster care, families, pregnant women, 
mental health and substance use disorder, elderly or people with disabilities. 
Table 2. 1. Age distribution of asthma patients (n=687) 
 
Table 2. 2. Gender distribution of asthma patients (n=687) 
 
Table 2. 3. Income distribution of asthma patients (n=687) 
Income Level 
Number 
(n) 
Percent 
(%) 
Cumulative 
Frequency 
Cumulative 
Percent 
Less than 25K 35 5.09 35 5.09 
Between 25K and 50K 482 70.16 517 75.25 
Between 51K and 75K 165 24.02 682 99.27 
Between 76K and 100K 5 0.73 687 100 
 
Table 2. 4. Insurance distribution of asthma patients (n=687) 
 
(b). Hospital admissions and medication adherence of asthma patients (n=687) 
Table 2. 5 summarizes inpatient admissions, Emergency department visits, office visits, 30 day 
readmissions and 90 day readmissions for the asthma population. Of 687 asthma patients, 148 
patients had inpatient admissions, 263 had emergency visits, 489 had office visits, 25 had 30 day 
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readmissions and 24 had 90 day readmissions. During the 2-year period on an average, asthma 
patients attended 3 (SD=4.25) office visits, had 2.3 (SD=2.4) emergency department visits, and 2 
(SD=1.8) were admitted into the hospital (Inpatient admission). Also, these patients had an 
average rate of 1.68 (SD= 1.14) 30-day readmissions and 1.9 (SD=1.8) 90-day readmissions into 
the hospital. 
 
Table 2. 5. Description of inpatient, emergency department, office visits, 30 day and 90 day readmissions 
for asthmatic population.  
Variables 
Inpatient 
admits 
(n=148) 
Emergency 
Department 
(n=263) 
Office 
Visits 
(n=489) 
30 day 
Readmissions 
(n=25) 
90 day 
Readmissions 
(n=24) 
Mean 1.91 2.35 3.25 1.68 1.96 
Standard Error 0.15 0.15 0.19 0.23 0.37 
Standard Deviation 1.82 2.42 4.25 1.14 1.81 
Sample Variance 3.31 5.86 18.08 1.31 3.26 
Minimum 1 1 1 1 1 
Maximum 14 18 65 5 9 
Total admissions/visits 283 618 1587 42 47 
Number of patients 148 263 489 25 24 
Female 84 (57%) 133 (51%) 255 (52%) 15 (60%) 15(63%) 
Male 64 (43%) 130 (49%) 235 (48%) 10(40%) 9(38%) 
 
Medication adherence was measured using variable Medication Possession Ratio (MPR) for 
control and rescue medication separately. The inclusion criteria for this study focused on patients 
with two or more fills of control medication. Table 2. 6 shows the number and percentage of 
asthma patients with control medication adherence, as calculated by their MPR, greater and less 
than the threshold of 80% (Briesacher, 2009) across age groups. By inspection, it appears that 
younger asthma patients are more adherent to control medication than older patients. The grand 
total at the end of the table for the two columns show that 213 (31% are adherent) have control 
medication adherence less than 80 and 474 (69% are non-adherent) have MPR more than 80. 
 
Table 2. 6. Control medication adherence for asthma patients across age groups (n=687) 
  Control medication adherence 
Age groups 
Less than or equal 80 (non –
adherent) #(%) 
More than 80 (adherent) #(%) 
0 to 9 90 (13%) 173 (25%) 
10 to 18 63 (9%) 123 (18%) 
19 to 29 7 (1%) 42 (6%) 
30 to 39 12 (2%) 51 (7%) 
40 to 49 12 (2%) 40 (6%) 
50 to 59 22 (3%) 36 (5%) 
60 to 69 6 (1%) 9 (5%) 
Grand Total 213 (31%) 474 (69%) 
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 (c). Sample description of non-asthmatic group 
A group of 972 non-asthmatic members were randomly selected i.e., none of these members had 
a primary or secondary diagnosis of asthma. These 972 members had continuous Medicaid 
eligibility with the same insurance company from January 2015 to December 2016. Of the 972 
members only 90 members had 180 inpatient visits for the study period. Therefore 90 non-
asthmatic patients were selected to be compared against asthma patients with inpatient 
admissions for this study. Reasons for inpatient admissions ranged from general health checkups, 
acute illnesses, chronic illnesses, and behavioral health related disorders. Diagnosis description 
and count of inpatient admissions for each diagnosis are attached in the Appendix B. 24% of the 
members (i.e. 22 members) had 30-day readmissions and 12% of the members (i.e. 11 members) 
had 90-day readmissions with minimum number of readmissions being 1 and maximum being 4 
readmissions. 8% of the non-asthmatic group members (i.e. 7 members) had both 30 day and 90-
day readmissions to the hospital.  
A cluster analysis was conducted on the non-asthmatic group in order to determine if all the 
individuals have the same behavior or to find groups, which are acting differently from the rest. 
This analysis was done to determine if was diverse enough to test the non-asthmatic group 
against the asthmatic group. Dividing the patients into 4 clusters is associated with an R square 
of 82.8 %, which means that the variation of the 4 clusters can explain 82.8% of the entire 
variation. Cluster analysis is done to identify homogenous groups that have similar behaviors but 
are distinctively different from the other groups. 90 members in the non-asthmatic group are 
therefore divided into 4 similar groups. At 4 clusters, the Pseudo F is very high with a value of 
138, which confirms the number of clusters found. In addition, the cluster history shows the 
components of each cluster (Appendix B) 
2.5.2 Correlational analysis for hypothesis #1 
A correlation analysis was performed to determine the relation between emergency department 
visits, inpatient admits, hospital readmissions (30 day and 90 day) with Control and Rescue 
medication adherence, as measured by their MPR.  
2.5.2.1 Correlation matrix with control medication: 
From table 2. 7., it can be noted that no variable is significantly correlated with Control 
medication adherence (MPR), as p-values are all greater than 0.05, but control medication 
adherence has a weak negative relationship with emergency department visits (r= -0.03886), 
inpatient admits (r= -0.00463) and 90-day readmissions (r= -0.00363). I.e. patient’s adherent to 
control medication will have less emergency visits and inpatients admits. Also, there is a weak 
positive relationship between control medication adherence and 30-day readmissions (r= 
0.03787), i.e. 30 day readmissions increase with increase in control medication adherence. 
Table 2. 7. Correlation Matrix for Emergency, inpatient admits, 30 and 90 day readmissions and Control 
medication adherence for asthma patients (n=687) 
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In addition, results (attached in Appendix C) showed that there’s a strong correlation between the 
number of emergency visits and the inpatient admits, between the number of Emergency visits 
and the 90 day readmissions, between inpatient admits and the 30 day readmissions, between 
inpatient admits and the 90 day readmissions, and between 30 day readmissions and the 90 day 
readmissions (p values < 0.05). Which means that any type of hospital utilization results in a 
subsequent admission ore readmission to the hospital. We can observe these correlations clearly 
in the scatter plots in Appendix B. 
2.5.2.2 Correlation matrix with Rescue medication:  
Table 2. 8. Correlation Matrix for Emergency, inpatient admits, 30 and 90 day readmissions and Rescue 
medication adherence for asthma patients (n=546) 
 
Rescue medication adherence refers to patients that took rescue medications at some point during 
the 2 years. Out of 687 asthma patients that took control medications, 546 patients also took 
rescue medications as needed. The correlation matrix in table 2. 8., evaluates the relation 
between all the hospital visit types and Rescue medication adherence. From table 2.2 it can be 
noted that a significant negative relationship exists between emergency department visits (r = -
0.14970, p value=0.0004) and inpatient admits (r = -0.09271, p value=0.0303) with Rescue 
medication adherence i.e. patients with rescue medication adherence have less number of 
emergency department and inpatient admits. 
In addition, results (attached in Appendix C) show that there’s a significant strong correlation 
between the number of emergency department visits and the inpatient admits, between the 
number of Emergency visits and the 90 day readmissions, between inpatient admits and the 30 
day readmissions, between inpatient admits and the 90 day readmissions, and between 30 day 
readmissions and the 90 day readmissions (p values <0.05). Which means that any type of 
hospital utilization results in a subsequent admission ore readmission to the hospital. We can 
observe these correlations in scatterplot attached in Appendix C.  
2.5.3 T-test for hypothesis #2  
In order to test hypothesis #2, evaluating if patients with more than 4 scheduled office visits for 2 
years had higher levels of medication adherence, a t-test was run between the two groups (coded 
as 0= patients with 0 to 3 office visits, 1= patients with office visits greater than or equal to 4) 
with control medication adherence and Rescue medication adherence. From table 2. 9., it can be 
noted that variances are equal (p-value is greater than 0.05), therefore we look at the p-value for 
“pooled” section. Since the p-value (0.6853) for the pooled section in the table 2. 9., is greater 
than 0.05, there is no significant difference. Patients with more than 4 office visits do not have 
higher level of control adherence as measured by their MPR. 
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Table 2. 9. T- Test for Control medication of patients with/without more than 4 office visits. 
 
Table 2. 10. T- Test for Rescue medication adherence for patients with and without more than 4 office 
visits. 
 
From table 2. 10, It can be noted that p-value for pooled section is 0.0063 (less than 0.05). 
Therefore patients with more than 4 office visits have higher levels of rescue medication 
adherence compared to patients with less than 4 office visits.  
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2.5.4 Regression analysis for hypothesis #3 
Regression analysis was used in order to explore the relationship between control medication 
adherence, type of medical visits (including, inpatient admits, emergency department visits, 30 
and 90-day readmissions), and demographics (age, gender, income). The scale of control 
medication adherence is if MPR is greater than 80%, patient is considered adherent; and if MPR 
is less than 80% patient is considered non-adherent First, the collinearity between the 
independent variables age, gender (coded as male=1, female=0) and income level are examined. 
No collinearity was found between any of the independent variables (age vs male, age vs 
income, and male vs income) (Attached in Appendix D). 
Table 2. 11. Regression analysis results for control medication adherence, emergency visits, inpatient 
admits, 30 day readmissions and 90 day readmissions vs Age, gender, income. 
 
Regression models were run for control medication adherence, emergency visits, inpatients 
admits, and 30 day readmissions and 90 day readmissions vs Age, gender, income. Backward 
elimination method was used. The table 2. 11, shows the equation for regression model before 
and after backward elimination. Also, from the results of regression analysis (Attached in 
Appendix D), it can be concluded that: 
 Control medication adherence has no relationship with age, gender, and income.  
 
Since the p-values for age (0.5342), gender (0.2785) and median household income 
(0.4134) are greater than 0.05 and after backward elimination, no variable is left in the 
model. Therefore no relation exists between the dependent and independent variables. 
 
 Emergency visits are influenced by gender and income. 
 
P-values for gender (0.0387) and median household income (0.0430) are less than 0.05, 
therefore emergency department visits are explained by gender and income. Therefore 
men and lower income patients have more emergency visits. All assumptions for 
residuals were satisfied.  
 
 Inpatient admits have no relationship with age, gender, and income. 
 
Since the p-values for age (0.2008), gender (0.8378) and median household income 
(0.5305) are greater than 0.05 and after backward elimination, no variable is left in the 
model. Therefore no relation exists between the dependent and independent variables. 
 
 30 day readmissions are influenced by age and median household income. 
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P-values for age (0.0616), and median household income (0.0662) are closer to 0.05. 
Therefore older patients and lower income patients tend to have more 30 day 
readmissions.  
 
 90 day readmissions have no relationship with age, gender, and income. 
 
Since the p-values for age (0.7033), gender (0.1488) and median household income 
(0.5773) are greater than 0.05 and after backward elimination, no variable is left in the 
model. Therefore no relation exists between the dependent and independent variables. 
2.5.5 T-test for hypothesis# 4  
A T-test was performed in order to test for hypothesis #4, readmission rates of asthma patients 
will be significantly different from readmission rates of non-asthmatic group. Asthma patients 
and non-asthmatic group patients with readmissions were included in this test and labeled as 
asthma patient=1 and non-asthmatic group=0. 
For 30 day readmissions: 
Table 2. 12., shows that in all cases, the null hypothesis of equal .means and equal variances are 
rejected. The p-value (0.0005) <0.05 for Satterthwaite method. Therefore we can conclude that 
30-day readmissions among asthma patients and non-asthmatic group are significantly different. 
For 90 day readmissions: 
Similarly, from table 2. 13., we note that the equality of variances (p value <0.05) is rejected. 
Since the equality of variances is rejected, Cochran and Satterthwaite approximations for the p-
value are used here. The p-value is almost equal to 0.05. Therefore, the 90 day readmissions for 
the two groups are significantly different. 
Table 2. 12. T-test results for 30 day readmissions among asthma patients and non-asthmatic group 
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Table 2. 13. T-test results for 90 day readmissions among asthma patients and non-asthmatic group 
 
Odds ratios: 
From table 2. 14 and 2. 15 it can be noted that asthma patients have lower chances of 30 day and 
90 day readmissions compared to non-asthmatic group ( odds of 30 day readmission is 0.117 
times non-asthmatic group [OR 0.117, 95% CI (0.062, 0.218)], odds of 90 day readmissions is 
0.260 times the non-asthmatic group [OR 0.260, 95% CI (0.123,0.551)]). 
Table 2. 14. Odds ratio of asthma patient and non-asthmatic group for 30 day readmissions 
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Table 2. 15. Odds ratio of asthma patient and non-asthmatic group for 30 and 90 day readmissions 
                                 
2.6 Conclusion and Discussion  
The current study explored the relationship between medication adherence and hospital 
utilization (inpatient visit, office visit, emergency department visit, 30 day hospital readmission 
and 90 day readmission) among Medicaid insured asthma patients. After conducting a statistical 
analysis, inpatient admits (p-value= 0.0004) and visits to the emergency department rates (p-
value=0.0303) of asthmatic patients were found to be significantly correlated to rescue 
medication adherence. Thus, patients that take their rescue medication tend to have less number 
of emergency visits and inpatient admits. Instinctively, this relation seems right. Asthma patients 
that understand their medication and use rescue medication in the event of an asthma attack tend 
to have lesser emergency department visits, and therefore fewer admissions to the hospital. 
In addition, results showed there was a strong positive correlation between the inpatient visits 
and 30 day readmissions (r=0.7634, p value <0.05), between inpatient visits and 90 day 
readmissions (r=0.7474, p value<0.05) as the r value is closer is to 1. Moderate positive 
correlation between 30 day readmissions and 90 day readmissions (r=0.4633, p value<0.05). 
Further, from the scatterplots (attached in Appendix b) and p values (Tables 7 and 8) it was 
found that emergency department visits were correlated to inpatient admits and 90 day 
readmissions. Although lower level of control medication adherence was expected to affect all 
types of visits to the hospital, the results showed otherwise. The correlations between the types 
of hospital visits were quite expected. As the number of inpatient admits increase the number of 
30 and 90 day readmissions also increase and as the number of 30 day readmissions increase, 90 
day readmissions increase. This is intuitive, as patients admitted to the hospital often end up 
being readmitted. Previous studies reported that one in five Medicare patients discharged from an 
inpatient facility end up in the hospital within 30 days (Nehi, 2012). Also, a study to assess 
factors that increase 30 day readmissions among asthma patients found that higher frequency of 
previous hospital utilizations like emergency department visits and inpatient admissions have 
higher likelihood to 30 day readmissions (Gonzalez-Barcala et.al, 2017). 
It is a known fact that patients with chronic conditions are often managed at their primary care 
physician’s (PCP) office. However, patients might see multiple PCP for their chronic conditions 
(Nehi, 2012). This study hypothesized that having more than 4 office visits per year, would 
benefit the patient and increase their medication adherence. This number of visits was derived 
from the standard of care for asthma patients. The results however showed that patients with 
more than 4 office visits do not have higher levels of control medication adherence, a possible 
reason for this result, could be the patient’s medical reason for the office visits (i.e., if the visit 
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was scheduled or unscheduled because of worsened conditions). This is a limitation of this study, 
since the reason for the office visit was not reflected in the insurance data. Knowing the reason 
for office visit would help better understand better the relationship among regular scheduled 
office visits and patients adherence to their prescribed control medication. Also, in case of 
sudden/ seasonal asthma attacks, the trip to the doctor’s office would often result in rescue 
medication being prescribed to control asthma. This is in lieu with the result of another t-test for 
patients taking rescue medications which showed that patients with more than 4 office visits tend 
to have higher levels of rescue medication adherence.  
Control medication adherence, emergency visits, inpatient admits, and 30 and 90 day 
readmission were checked against age, gender and income, to understand their relationship. 
Control medication adherence, inpatient admissions, and 90 day readmissions had r square 
values nearly equal to 0 and showed no relationship with age, gender or income level. 
Emergency visits were influenced by gender and income level i.e. men and low-income asthma 
patients tend to have more Emergency Department visits. Similarly, 30 day readmissions are 
influenced by age and median household income, i.e. older and low income patients tend to have 
30 day readmissions. 
Lastly, 30 day readmissions and 90 day readmissions among asthma patients and non-asthmatic 
group were significantly different at 5% significance level. Non-asthmatic group for this study 
was a mix of Medicaid insured members without asthma (might or might not have other 
illnesses). Although this test does not tell us much, it is interesting to see that 30 day 
readmissions among the two groups was significantly different. The chances of 30 day and 90 
day readmissions is lower among asthma patients compare to non-asthmatic group.  
Previous studies reported that adherence to control medications among asthma patients varies 
between 40% and 60%, with 80% and above being the threshold of good medication adherence 
(Menckeberg et al., 2008). Average control medication adherence for our population is 82%, 
with 474 out of 687 (i.e., 69%) of the patients adhering to their control medications. 283 patients 
(41%) had inpatient admissions and 7% of these patients were readmitted into the hospital within 
30 and 90 days. The present study did not find any relationship among control medication 
adherence and any type of hospital visits (emergency department visits, inpatient admits, office 
visits, 30 and 90 day readmissions), while rescue medication adherence was related to 
emergency department visits and inpatient admits. Office visits did not seem to improve control 
medication adherence but they increased rescue medication adherence among our study 
population. Male and low income patients tend to have more emergency visits and older and low 
income patients have more 30 day readmissions. 
2.6.1 Ethical considerations 
IRB committee approval was taken prior to beginning the study and efforts were taken to protect 
confidentiality of subjects. Data have been appropriately cleaned and de-identified. Evidence for 
reliability and accuracy of data was validated by the data analytics team at the insurance 
company. 
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2.6.2 Study Limitations and Assumptions 
Some of the limitations encountered in the study include possible human error as claims and 
other data used in the study is entered and handled by designated person. Demographic 
information such as race, ethnicity, marital status etc. and also reasons for office visits were not 
available. Discharge instructions given by the doctor after an inpatient admission were not 
available and hence it would be hard to track if a medication was discontinued or the strength of 
the medication was reduced due to the doctor’s orders or the patient’s negligence. The current 
study may not have external validity or generalizability for asthma patients as the study sample 
was small and only consisted of patients from one insurance company in the state of Louisiana. 
Assumptions made in the study are prescriptions filled are assumed to be prescriptions consumed 
and it might not actually be the case. 
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CHAPTER 3: PAPER #2 
 
“Selection Criteria for Intervention to Improve Medication Adherence for Medicaid insured 
Asthma Patients”, proposed submission to the International Journal of Health Care Quality 
Assurance. 
3.1 Abstract 
The benefits of asthma medications have been well documented, yet poor medication adherence 
is often reported among asthma patients. Uncontrolled asthma is associated with a long list of 
events such as missed school days; reduced productivity; quality of life; social functioning; 
family distress; inflated healthcare costs; hospitalizations; and hospital readmissions (Baena-
Cagnani et al., 2001). Medication adherence rates are as low as 50% in children and 30%-70% 
among adults (Bateman et al., 2008; Milgrom et al., 1996). Asthma results in hundreds of 
millions of dollars in healthcare costs – costs that are largely preventable. Medication non-
adherence varies across diseases, individuals and across time (Sewitch, 2004), but is prevalent 
among asthmatic patients. Poor medication adherence leaves a larger percentage of patients 
vulnerable to sudden asthma attacks, hospitalizations and might even result in potential 
emergency department visits or hospital readmissions. In order to develop interventions and 
improve medication adherence, understanding reasons for non-adherence is important. This 
paper focuses on identifying key factors and barriers of medication non-adherence among 
Medicaid insured asthma patients in Louisiana and recommends potential interventions. The two 
types of insurance coverages (Temporary Assistance for Needy Families and Supplemental 
Security Income-Non Dual) were the only significant predictors of control medication adherence 
among the factors analyzed (with p-values =0.0001). Asthma patients with TANF and SSI- Non 
Dual coverages are less adherent to control medication adherence compared to other coverages. 
Also, control and rescue medication adherence was not significantly different among case 
managed and non-case managed asthma patients. 
3.2 Introduction: 
According to the National Health Interview Survey conducted in 2014, there are as many as 24 
million people diagnosed with asthma in the United States (CDC). Asthma is a chronic illness 
that causes variable degrees of airflow obstruction due to inflammation of airways, increased 
mucus secretions, constriction of smooth muscles of bronchi and airway remodeling in the lungs. 
Asthma is classified into four-severity levels namely intermittent, mild persistent, moderate 
persistent and severe persistent asthma (NAEPP, 1997; Taitel, Allen, & Creer, 1998). Certain 
triggers such as irritants, allergens, viral or bacterial infections, exercise or strenuous work, 
seasonal changes, and a few others cause sudden asthma attacks or exacerbations among 
patients. Triggers for asthma symptoms vary among individuals and they often cause episodes of 
wheezing, breathlessness, chest tightness, low oxygen levels, shortness of breath and coughing 
(NAEPP, 1997). Therefore there are multiple reasons for an asthma patient to appear at 
emergency departments and asthma management is a priority as it results in costly 
hospitalizations and even death in some cases.  
 
Although there is unanimous agreement on medications being primary tools to prevent 
complications and manage chronic conditions, numerous studies show that medication adherence 
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among chronically ill patients is only 50-60 %. Patients need to follow their medication and get 
refills on time to lessen the occurrence of adverse events and to increase their quality of life. 
Education/knowledge about illness, targeting high-risk populations, evaluating interventions in 
the home environment, and preventive treatment and relief (through medication) from the attacks 
are some of the known interventions to effectively keep asthma control in check (CDC, 1996). 
This study focuses on finding barriers/ factors affecting medication adherence among asthma 
patients, identifying gaps in providing care (such as case management services) and proposing 
effective patient selection criteria for intervention to assist in reducing healthcare costs 
associated with medication non-adherence. 
3.3 Literature Review 
3.3.1 Asthma in Louisiana 
In Louisiana, an estimated 7.7% (270,261) adults, 18 years of age and older, suffer with asthma 
(CDC, 2014). Louisiana Department of Health (DHH) reported that 33 parishes have average 
adult asthma prevalence rate higher than 6.7% (2010 asthma prevalence rate) and 11 parishes 
(De Soto, E. Feliciana, Richland, Sabine, St. Bernard, St. John the Baptist, Tensas, Vernon, 
Washington, W. Baton Rouge, and W. Carroll) have average adult prevalence rates (2006-2010) 
that are higher than the 2010 asthma prevalence for the United States (8.8%). Reports indicate 
that one in ten (10.7%) Louisiana households with children had at least one child who was 
asthmatic (DHH, 2011). According to the factsheet by DHH in 2011, 22.7% of high school 
students have reportedly missed more than one school days due to asthma. Due to increasing 
prevalence of asthma among children and subsequent missed school days, a law called Louisiana 
ACT 145 came into effect in the year 2009, making Louisiana the 49th state in the U.S. to allow 
students to carry asthma medications in school. The bill was passed to eliminate the need to 
retrieve medications from nurse or offices at school at first signs of asthma attacks. 
3.3.2 Asthma Treatment and Care 
Expert Panel Reports (EPR) serving as guidelines for diagnosis and management of asthma, are 
developed under the National Asthma Education and Prevention Program by National Heart, 
Lung, and Blood Institute. Since the nature of asthma symptoms is erratic, it needs continuous 
assessment and changes to the patient’s treatment plan.  According to the latest Expert Panel 
Report (EPR- 3) developed in the year 2007, every person with asthma should have a written 
asthma action plan. Typically, an action plan is developed by the doctor and tailored for each 
individual patient depending upon the severity and other details of their illness. An asthma action 
plan is a daily treatment plan containing measures to be taken in case of asthma attacks or 
exacerbations, identifying need to seek doctor/emergency department visit, detailed description 
of long-term control treatment, and information on what medication is to be taken at what time 
(NAEPP, 2007). Schools, day cares, guardians, family and friends need to know of a child’s 
asthma action plan and should be ready in case of emergencies (CDC, 2011).  
Treatment goals for asthma are to control symptoms, prevent asthma attacks and reduce 
exacerbations. At the beginning of an asthma treatment, patients are scheduled to visit their 
doctors every 2 to 6 weeks and a comprehensive asthma action plan is developed to manage care. 
Once the asthma is controlled they can be scheduled to meet the doctors once a month to twice a 
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year depending on their health and signs of symptoms (NHLBI, 2014). Pulmonary function is 
monitored regularly among asthma patients (especially among older patients) using peak flow 
meters in order to avoid severe obstruction of airflow (NAEPP, 2007). Peak flow meters are 
small hand held devices used to determine the degree of obstruction in the airways and severity 
of asthma symptoms (Elana, 2011). Peak flow number shows how well a patient’s lungs are 
working while the patient is resting. They are used in emergency departments and clinics to 
quickly assess patient’s condition. Patients and their families are educated on usage of Peak flow 
meters to be used at home for efficient treatment (Self, 2005).  
3.3.3 Asthma Medication  
Doctors prescribe asthma medication depending on the type of symptoms some medications are 
used to reduce inflammations and swelling in the airways, while others are used to relax the 
airways, some medicines are prescribed to be taken even in the absence of symptoms to prevent 
any sudden deadly attacks (DHH, 2011). According to the National Asthma Education and 
Prevention Program, rescue and control medications are two main categories of asthma 
medications. (i) Rescue medication/short-term medication: Acute exacerbations of symptoms 
such as coughing, wheezing, chest pain etc. are treated using rescue or short acting medications. 
These come in three classes, short-acting beta-agonists, anticholinergics, and systemic 
corticosteroids. They are used for instant relief in case of sudden asthma attacks. They are also 
called as short-term medication. (ii)Control medication/ long-term medication: Persistent 
symptoms such as inflammation or bronchospasms are controlled using control medications. All 
asthma control medications were developed to reduce symptoms, improve asthma control, 
improve quality of life, prevent exacerbations, and reduce the need for emergency department 
usage, hospitalizations and death due to asthma attacks (NAEPP, 2007). There are 8 classes of 
control medications: (a) inhaled corticosteroids (ICS), (b) cromolyn sodium and nedocromil, (c) 
immunomodulators, (d) systemic corticosteroids, (e) leukotriene receptor antagonists (LTRAs), 
(f) 5-liopxygenase inhibitor, (g) long-acting beta-agonists, and (h) methylxanthines. They are 
also called long-term medication. 
Asthma medications are available in either pill or liquid form to be taken by mouth, injections or 
inhalers. Inhalers are most effective and widely used hand held devices used to deliver asthma 
medications directly into lungs. Different types of inhalers are available for use. Some of the 
inhalers dispense one medication while others are used for combination therapy, meaning they 
contain two different medications. Metered dose inhalers (MDI), dry powder inhalers (DPI) and 
nebulizers are different types of inhalers used to deliver asthma medication in different ways. 
Metered dose inhalers are canisters containing asthma medication. When the inhaler is pushed, 
medication is sprayed through it and needs to be breathed in by the patient. Dry powder inhalers 
deliver medications in the form of dry powder. These type of medications are hard to breathe in 
during an asthma attack. Nebulizers are simple devices where medications are delivered through 
a mouthpiece or a mask. They are easier to use and are recommended in case of severe asthma, 
as patients can breathe normally while taking the medication (WebMD medical reference, 2015). 
In order to lead a normal active life, asthma patients are advised to always have their medication 
available and adhere to them as per their prescription. 
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3.3.4 Medication adherence and non-adherence: 
Chronic illnesses are highly prevalent as about half of all adults in the U.S. (117 million) and 
approximately 40% (133 million) of the total population have one or more chronic conditions. 
This number is projected to increase to 157 million by the year 2020 (Lancet, 2009). 75% of 
healthcare costs are incurred by chronic conditions and four of the most expensive healthcare 
conditions are namely: heart diseases, cancer, mental disorders, and pulmonary conditions 
(Stanton, 2006). Majority of the patients with chronic diseases are prescribed to follow lifelong 
medication in order to control their conditions and avoid complications. Medication adherence is 
a key component. It is defined as ‘the extent to which patients follow the instructions given in 
their prescribed treatments’ (Haynes et al. 2005). Medication adherence is often studied in terms 
of non-adherence, as non-adherence to medication leads to health complications, financial crisis 
and poor disease management (Haynes, 2008; Munger et al. 2007). Absence of treatment results 
even after prescribing effective medications, led physicians to look into the concept of non-
adherence (Rapoff, 1997). Medication non-adherence is taking less medication than prescribed, 
or patients not refilling their prescription after the initial fill. About 33% to 69% of medication 
related readmissions are due to non-adherence (Osterberg, 2005). Medication adherence is 
alarmingly low among patients with chronic conditions and approximately one half of these 
patients do not take medications as prescribed by their providers. Poor medication adherence 
lead to approximately 125,000 and $100-$300 billion direct and indirect costs every year in the 
U.S. (McCarthy, 1998; Mahoney, 2008). 
In spite of a detailed asthma action plan, many patients take asthma medications only when they 
experience asthma symptoms or attacks and reduce or completely stop using medications during 
long symptomless periods. Patients can be completely adherent, completely non-adherent or 
have sporadic pattern of adherence. Poor medication adherence is of great concern for physicians 
when it comes to medication or dosage selection (Creer & Bender, 1995). A study on asthmatic 
patients reported a range from 30% to 70% for adherence to medication, and that adherence to 
regular preventive drugs are even lower, about 28% in developing countries (Bender et al., 1997; 
Reid et al., 2000; Pearson et al., 1999). 
Non-adherence results in increased use of expensive healthcare services which end up costing 
more time, money and efforts (such as, emergency care, special care, primary care provider 
visits, more medications, hospital services etc.) than treating the original condition. It is also 
associated with poor health outcomes, premature deaths and hospital readmissions (Braithwaite 
et al., 2013). Research shows that medication non-adherence is related to more than one-third of 
medication related hospital visits and 40% of nursing home visits (PhRMA, 2012; APha, 2004). 
Therefore, it is important to assess the level of medication adherence among chronically ill 
patients to introduce interventions, if needed, to increase medication adherence and health 
outcomes. Medication adherence can be measured by:  
 Subjective measurements include maintaining medication dairies, self-reporting tools, 
questionnaires and surveys (Elliott, 2006). Morisky’s scale, is an example for widely 
used self-reported measure of adherence, the scale consisted of four questions, and a 
negative answer to any of those four questions was considered as non-adherence (George, 
2007). Many such self-reported adherence scales have been developed and validated. 
 Objective measures include pharmacy data, electronic measurement devices, biologic 
assays; measurement of testing serum, urine, saliva, and tablet counts, canister weights, 
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etc. Biological assays are invasive and do not give long term results, technology based 
measurements are ineffective if patients do not use the inhalers properly and pharmacy 
data assists in evaluating medication behavior of the patients and  insufficient filling of 
prescriptions are an indicator of patients who are likely non-adherent but this data could 
have discrepancies (Hess, 2006).  
In summary, in order to measure medication adherence, an ideal study would include both 
objective and subjective methods but in case of time constraints or cost related issues, 
objective measure alone can be calculated with consistent pharmacy claims data. This study 
will conduct both objective and subjective techniques to measure and understand medication 
non-adherence among the studied population.  
3.3.5 Factors Affecting Non-adherence  
Treatments are only effective when patients adhere to them. Despite the availability, proven 
significance in preventing complications, improving health outcomes and reducing asthma 
related deaths, non-adherence to medication remains a significant problem. Though numerous 
studies on medication non-adherence and factors affecting adherence exists in literature, there is 
no consistency in the reported results. A study on adherence and healthcare costs summarized 
literature on medication non-adherence by categorizing factors. Categories specified in previous 
studies are patient related factors such as demographic (age, gender, income, family size, marital 
status), sociocultural (medication beliefs, health literacy, side effects or threats, social standing 
and network) and behavioral data (mental illness, stress, substance abuse, cognitive function). 
Healthcare provider related factors include communication and provider-patient relations (Iuga, 
2014).  
A study in Korea on identifying factors that can predict medication adherence among elderly 
people found that education level, health-related problems, dosing frequency, satisfaction with 
patient counseling and explanation of medication were the main contributors to medication non-
adherence (Jin et al., 2016). According to the Harris Interactive 10,000 patient’s survey 
conducted in 2002, Among 9,412 patients that participated in the survey, 24% reported 
forgetfulness was the main reason for non-adherence followed by 20 % patients reported side 
effects, 17 % patients as high drug costs and 14% of respondents reported patient’s perception of 
medication effectiveness (Boston Consulting Group, 2003). Number of medications were 
recognized as a factor for lower levels of adherence, as requirement of taking multiple 
medications at variable intervals in a day is associated with non-adherence among older patients 
(Ickovics & Meisier, 1997; Bedell, 2000; Claxton, Cramer, & Pierce, 2001). A cross-sectional 
survey of 24,017 adults with asthma, hypertension, diabetes, hyperlipidemia, osteoporosis, or 
depression found that 67% agreed that they forget to take medications, 37% of respondents ran 
out of medications and 23% reported they were careless about taking medications sometimes 
(Gadkari & McHorney, 2010). Adherence to pulmonary medication was found to be as low as 
30% among adolescents. (Dekker, 1993). 
Evidence shows that reasons for medication non-adherence among asthma patients are complex 
and multifold. Factors found in the literature are listed below. 
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3.3.6 Patient Related Factors 
Age and gender: Many studies have found that age is risk factor for medication non-adherence 
and most of them agreed that older age is associated to non-adherent behavior (Jonasson, 1999; 
Strunk, 2002). Although some papers found that females were more non-adherent to medication 
than males, Jonasson and Strunk found no such difference in their research. 
Race and ethnicity: A study on examining differences between white patients and African-
American patients with asthma found that African-American patients showed poorer medication 
adherence compared to white patients. Additionally, white females were found to be non-
adherent compared to white males (Willliams, 2007).  
Socioeconomic: A study on factors affecting adherence in asthmatic children evaluated 
preventive medication use among fifty one children for 1 month using electronic monitoring 
device and found that child’s age, family income and parent’s level of education did not affect 
medication adherence, but parental stress, forgetting medication or child’s reaction to medication 
were reported by parents as the main factors. By comparing the actual usage of medication and 
parent’s perspective from a questionnaire, parents were found to report overestimated medication 
use (Burgess, Sly et al. 2008).  
Sociocultural: A cohort study of elderly asthma patients found that negative attitude towards 
inhaled controller medications, family dysfunction, psychological adjustment, and depression are 
risk factors for poorer adherence (Krauskopf, 2013). An 18-month study on fill patterns of 
underserved children with asthma revealed that filling of controller medication was lower than 
prescribed, while rescue medications were filled abundantly. Side effects from medication, low 
asthma and medication knowledge was found to be the barrier in this study (Bollinger, 2013). 
Disease related: A study found that adherence to asthma medication was affected by 
comorbidity, adverse reactions to medications disease severity (Charach, 2008), and long 
symptom free period. 
Medication related: According to a study on patient preferences for enhancing adherence, too 
many pills, side effects, lack of information on the benefits of medication, physician and patient 
relationship were reported as a few factors to be tackled (Cascade, 2010). Other factors include 
children’s understanding of taking medication (Charach, 2008), regimen complexity, and 
frequent doses (Viswanathan, 2012; Morisky, 2008; Battistella, 2016). 
Other factors include: lack of transportation, physician and patient relationship (Martin, 2005), 
healthcare locations, and disruptions in lifestyle.  
 
The literature on asthma studies shows that the factors influencing medication adherence are 
broad and a more thorough understanding is necessary to address this issue. Most studies in the 
past have used correlation or regression analysis to find associations between medication 
adherence and a variety of factors or predictors appropriate to the population being examined 
(Rapoff, 2010). This paper also used correlation and multiple logistic regression analysis to 
examine factors affecting medication non-adherence among asthma patients. 
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3.3.7 Current Methods to Improve Medication Adherence  
Numerous interventions were developed over the years to improve patient’s adherence to 
medication such as dosage modification, reminder systems, adherence packaging, drug 
education, side effect management, self-monitoring (Chen, 2010), and intervention through 
pharmacists, physicians or nurses etc. Some of the current interventions methods are discussed 
below: 
1. Educating patients to promote medication adherence by healthcare providers: 
Explaining the importance and discussing any reluctance to take medications has 
been considered as an educational intervention and it is quite successful in most 
chronic illnesses (Ratanawongsa, 2013). Attempts to improve adherence through 
written education alone turned out to be unfruitful therefore, Nicholoas-English, 
DiMatteo and Cascade E, in their respective studies suggested to embrace patient 
centered activities that empower them (Nicholas-Green, 2000; DiMatteo,M.R, 
2004; Cascade, 2009). These patient-centered activities could be a combination of 
written, verbal and other approaches that educate patients on their overall 
adherence.  
2. Intervention through monitoring patient activity: A randomized clinical study on 
Internet-based monitoring of asthma among 300 patients was conducted in the 
year 2005. Patients were randomly assigned to three groups monitoring by 
specialist, monitoring by general practitioner, and home telemonitoring through 
Internet (Intervention group). A 6 month long study concluded that intervention 
group of home telemonitoring through internet reported lesser asthma symptoms 
during the study period than the other two groups and were found to have better 
pulmonary function and quality of life (Rasmussen et al., 2005). Few other studies 
reported similar results for Internet based interactive methods among asthma 
patients (Jan et al., 2007; Guendelman et al., 2002). 
3. Health coaching: Heath coaches are being used in primary care settings to help 
patients cope with one or multiple chronic diseases. Medication adherence 
counselling and collaborative communication are facilitated by these trained 
professionals in clinical settings to improve health outcomes (Thom et al., 2015). 
A study on impact of health coaching on medication adherence among patients 
with three poorly controlled illnesses, type 2 diabetes, hypertension and or 
hyperlipidemia for 12 months found that health coaching significantly increased 
medication adherence (10%). 
4. Packaging interventions: Blister packs, unit-packaging, pill boxes, unit of dose 
packaging and monitored dosage systems are some of the examples of packaging 
interventions currently in use to improve medication adherence. Single use 
packaging of medications by a professional is called a blister pack, these are 
generally recommended for adults with multiple chronic conditions (Mahtani, 
2011).  
5. Case or illness management for chronic illnesses: Case management services 
emerged in 1990s as a strategy to manage and coordinate care using nurses and 
other resources to impart knowledge on self-management skills, reduce 
readmissions, improve quality, discharge planning, consistency and administer 
cost effective care for chronic illnesses (Rosenthal, 2008; Joo, 2014; Berg, 2015). 
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Although the definition of case management is ambiguous, the goal for all the 
case management services stand the same. Licensed professionals are appointed 
as case managers to high risk or patients in need to assistance. Generally, 
physician visit reminders, follow up phone calls, health assessment, and planning 
depending upon the requirements of the client. These services are designed to 
provide safety, efficiency and patient centeredness. 
 
A study by Boyd showed significant reduction in hospitalization rates after 1 year of case 
management intervention compared to usual care group of patients (Boyd, 1996). 
Woohyun et al, focused on using mobile computing, medical sensors and communication 
technology for supportive communication between adolescents with asthma and case 
managers, the findings of this study were consistent with literature and has identified the 
usefulness of interaction between clinician and patient, successful information exchange 
and patient centeredness of case management services (Yoo, 2015).  
3.3.8 Strategies to improve medication adherence  
Medication adherence is a particularly important health-related behavior for many people faced 
with complex therapeutic regimens and/or chronic illnesses. A combination of several simple 
strategies, such as more thorough patient instructions, reminders, pill containers, self-
management plans and phone follow-up, have been found to improve adherence and treatment 
outcomes (De Geest et al. 2006, Haynes et al. 2008). Patient education alone has not been found 
to be sufficient to change and sustain adherence to medication (Sabate 2003). Interventions that 
focus on the whole person and the therapeutic relationship are needed to improve health 
outcomes (Sabate 2003, Maizes et al. 2009). 
Many of the interventions though effective are undesirable in many cases as they are expensive, 
have low external validity, labor intensive, complicated to carry out, not extremely effective and 
can be carried out for small durations only (Bender, 2015). Interventions should be tailor made 
for the target population and disease condition as a single intervention cannot be expected to play 
an effective role across all patients, establishments and conditions (Burkhart & Sabate, 2003). 
Improving medication adherence might be the best investment for tackling chronic conditions, 
enhances patient safety and health system effectiveness, reduces poor outcomes and associated 
health care costs (Burkhart & Sabate, 2003). 
3.3.9 Research gaps 
Failure to take asthma medication as prescribed has many consequences, few of which include 
poor health, increased healthcare costs, and increased service utilizations. Even though there are 
established guidelines for management of asthma such as EPR-3, GINA etc. adherence to asthma 
medications have not significantly improved over the years. Services and interventions such as 
telemonitoring, asthma health education, self –management education, and case management 
services etc. have been set up for improved healthcare outcomes. Case management services 
have been established in the 1990s and reduce the gap between patient and healthcare services. A 
physician might not be able to dedicate more than his scheduled time for the doubts and concerns 
of every patient, due to their busy schedule. Therefore, nurses, healthcare officials and other 
trained resources as case managers help bridge the gap between patient and healthcare services, 
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encourages self-management of their illnesses, address their concerns and be a continual member 
in their healthcare journey.   
Understanding factors resulting in medication non-adherence is important to improve medication 
adherence behavior in patients and in turn reduce the readmission rates of asthma patients. Large 
body of investigations on this topic are available but very few studies attempted to determine the 
influence of case management services on medication adherence. Most studies focus on its effect 
on reducing hospitalizations and readmissions. Most of the research concerning medication 
adherence in asthma is covered in healthcare journals and revolves around finding the factors 
only. Therefore, there is a clear gap in the knowledge of the role of case management services in 
improving medication adherence behavior for asthma patients. 
3.4 Materials and methodology 
3.4.1 Objective of the study  
In order to develop interventions and improve medication adherence, understanding reasons for 
non-adherence is important. The objective of this study is to identify key factors and barriers of 
medication non-adherence among Medicaid insured asthma patients and recommends potential 
interventions. An additional objective is to propose effective patient selection criteria for 
intervention that will improve medication adherence rates.  
3.4.2 Subjects 
The study population includes Medicaid asthma patients, insured by Insurance company from 
January 2015 to December 2016 with maximum of 45 days of enrollment gap from the 
insurance, have had taken prescribed asthma controller medication during the study period 
(January 2015 to December 2016), and have had one or more hospital claims (Inpatient stay) 
with primary or secondary diagnosis of asthma are the subjects in the study.  
3.4.2.1 Participant inclusion criteria 
 Patients with at least one refill of asthma medication and at least one or more hospital 
claims of primary or secondary diagnosis of asthma during the study period will be 
included.  
 Patients with a maximum of 45-day enrollment gap with the insurance are considered. 
3.4.2.2 Participant exclusion criteria 
 Patients with interrupted claims data history (<6 months) during the study period. 
 Medical claim that is not related to asthma treatment (such as an accident, sprain etc.). 
 Pharmacy claim during the study period for any reason other than asthma medication. 
 Patient that discontinued insurance with the insurance company during the study period. 
 Missing invalid data on claims and demographics.  
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3.4.3 Dependent variables 
The dependent variable for this study is Medication adherence and the Medication Possession 
ratio (MPR) will be used to measure medication adherence in this paper. Following is the 
formula of MPR.  
MPR =  
Total number of days covered
(Number of days in measurement period) + last fills supply
 x 100 
1. To calculate the numerator, the study period was determined (2 years for this study) and 
all the days supply of asthma medication obtained from claims data was summed to get 
total number of days covered. 
2. The total number of days covered were then divided by the number of days in the study 
period plus the last fills days supply and multiplied by 100 to obtain MPR for one patient. 
3. If the number was greater than 80% Patient was considered adherent and lesser than 80% 
was considered non-adherent. 
3.4.4 Independent variables 
The independent variables include patients’ age, gender, income level(socioeconomic indicator 
by zip codes), number of inpatient visits, number of ED visits, number of 30 day and 90 day 
readmissions to a facility, type of insurance, and enrollment in case management services.  
3.4.5 Selection Criteria for Case management 
Effect of case management on medication adherence behavior is an integral part of this study. 
Information on the selection criteria for patients to be case managed, procedure that follows, the 
role and interaction of case managers with members was documented. Risk utilization reports 
consisting of details on frequency of resource utilization, unit cost, and time to event are the 
main triggers for selecting potential patients that need case management. Once the patients are 
identified they are referred for case management and are contacted by the company for approval 
on being case managed. 
3.4.6 Data Source: 
Data for this study was obtained from software databases namely Microstrategy and EDW data 
warehouse used by the insurance provider company. The data comprises of patient information, 
medical claims, outpatient claims, and pharmacy claims. Since the study population only consists 
of asthma patient’s asthma ICD, procedure and medication codes were used to identify asthma 
patients from all the members in the insurance plan. 
1. ICD 9 (493.XX) and ICD 10 (J45.XX) codes for asthma. Codes used in the study are 
attached as Appendix A. 
 
2. Procedure codes (Attached in Appendix F) of most commonly used resources by asthma 
patients. E.g.: Code 94010 for spirometry, including graphic record, expiratory flow rate 
measurements. This procedure is commonly used to determine the pulmonary function 
among asthma patients. A list of such most common procedures for asthma patients were 
created to identify population that used asthma services. 
 
52 
 
3. Complete list of asthma medication available in the HEDIS 2015 asthma medication list 
is the third component used in obtaining asthma population. Each drug in the HEDIS 
medication list has a NDC (National Drug Identifier) number. NDC code is a 10 digit, 3 
segment unique identifier for each medication. Labeler, product and trade package are the 
3 segments of the identifier number. Medications of drug categories namely short-acting 
beta agonists, oral corticosteroids/systemic corticosteroids, inhaled corticosteroids, 
combination medications, long-acting beta agonists, leukotriene receptor agonists, 
immunomodulators, cromolyn sodium, nedocromil, and methylxanthines were part of the 
list and were used to determine the population taking asthma medications. Asthma 
medication list by HEDIS is attached as APPENDIX G of this paper. 
The combination of all the above three steps that is ICD codes, procedure codes and asthma 
medication list are used to identify asthma patients/members in the insurance plan or have 
undergone any special procedures or taken medication related to asthma.  
3.4.7 Data collection:  
(i). Hospital data was collected for demographic information such as age, gender, Zip codes 
(indicator of socioeconomic standing of the member), office visits, ED visits, inpatient stay, and 
primary care physician. (ii). Economic data such as median household income was not available 
for the study. However, this study used the economic indicator data by zip codes provided by the 
United States Census Bureau to report median household income. (iii). Medical claims data was 
collected to obtain information such as date, place, and type of service, procedure performed, 
cost charged and covered per service. (iv). Pharmacy records helped understand the medication 
history. It included the following: Name of the medication, day of prescription fills, number of 
refill, dosages, medication counts and, duration of medication/ day’s supply. (v). Insurance 
information: patients enrolled in case management or any other disease management services, 
insurance eligibility for the study period etc. (vi). Interviews with insurance professionals were 
conducted to get an idea of types of insurances offered, eligibility criteria for it, and eligibility 
criteria to enroll in case management services. (vii). Group interviews were conducted with the 
Chief medical affairs director, case managers, and pharmacy officials for clear understanding on 
the working techniques in the insurance company. (viii). Telephone interviews were to be 
conducted for a random sample of 30-case managed members and 30-non case managed 
members originally, but only 12 case managed and 15 non case managed patients participated in 
the interviews. The Interview consists of 20 questions related to the member, illness (asthma), 
physician, and medication related. The interview procedure and questions are attached in the 
appendix A. Each typical phone call lasted 10 minutes. 
3.4.8 Hypothesis testing 
 H1: Levels of control medication adherence for asthma patients will differ by   
o Age, gender, number of inpatient visits, number of ED visits, number of 30 day 
readmissions to a facility, type of insurance eligibility, and number of medications 
will affect prescription adherence. 
H2: The insurance company offers several services to help asthmatic patients manage 
their illness at their home, such as case management services. Patients who receive these 
services will have higher levels of prescription adherence. Levels of prescription 
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adherence for asthma patients will differ among Case Management and non-asthmatic 
group. 
3.4.9 Data Analysis:  
Descriptive statistics was conducted on the sample to analyze characteristics of the data. (i) To 
address H1a Multivariate logistic regression model was built by backward elimination method to 
determine the association of variables of interest such as age, gender, income level, type of 
insurance, enrollment in case management services, number of ED visits, number of inpatient 
visits, number of 30 day readmissions to a facility with control medication adherence for the 
asthma population. (ii) To address H2 a t-test was performed to see if case managed patients 
have higher levels of prescription adherence. (iii) Telephone interview results were analyzed to 
identify objective measure of medication adherence and point out barriers to medication 
adherence with respect to the study population. All the analysis required in the study was 
conducted using SAS. 
3.5 Results 
3.5.1 Sample description 
Patient population for this study consists of 687 asthma patients that fulfilled the inclusion 
criteria. Of these 687 patients 41 (6%) patients are case managed by the insurance company. A 
summary of the descriptive statistics of the study population is shown in the table 2. 16., below. 
The average age was 20 years, with the youngest patient being 1 year old and the oldest being 65 
years old. Most patients (65%, 449) are considered minors, under the age of 18. 384 (56%) of the 
patients were females, while 303 (44%) were male. According to the 2016 U.S Census bureau 
income statistics, 75% (517) of the households received $25,000 to $50,000 approximately, per 
year.  
Table 2. 16. Patient demographics of asthma patients (n=687). 
Variable Number (n) Percent (%) Cumulative 
Frequency 
Cumulative 
Percent 
Age         
0-18 years 449 65.36 449 65.36 
18-29 years 49 7.13 498 72.49 
30-39 years 64 9.32 562 81.8 
40-49 years 52 7.57 614 89.37 
50-59 years 58 8.44 672 97.82 
60-69 years 15 2.18 687 100 
Gender         
Female 384 55.9 384 55.9 
Male 303 44.1 687 100 
Income Level         
Less than 25K 35 5.09 35 5.09 
Between 25K and 50K 482 70.16 517 75.25 
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Variable (Cont’d) Number (n) 
(Cont’d) 
Percent (%) 
(Cont’d) 
Cumulative 
Frequency 
(Cont’d) 
Cumulative 
Percent 
(Cont’d) 
Between 51K and 75K 165 24.02 682 99.27 
Between 76K and 100K 5 0.73 687 100 
Insurance coverage         
Behavioral Health 7 1.02 7 1.02 
CHIP 2 0.29 9 1.31 
Foster Care 17 2.47 26 3.78 
Medicaid Expansion 153 22.27 179 26.06 
SSI Non-Dual 87 12.66 266 38.72 
TANF 421 61.28 687 100 
 
3.5.2 Medication adherence: 
Medication adherence was measured using variable Medication possession ratio for control 
medication and rescue medications separately. MPR for rescue adherence and control adherence 
are shown in the table 2. 17. below. All MPR values were truncated and do not exceed 100 %. 
On an average, asthma patients (n=687) showed 82.3% (SD=26.2) control medication adherence. 
546 out of 687 patients took rescue medication during the study period and showed 60% 
(SD=34.6) rescue medication adherence. 
Table 2. 17. MPR for Control and Rescue medications. 
Variables 
MPR for control 
adherence (n=687) 
Rescue medication 
MPR (n=546) 
Mean 82.36 59.82 
Standard Error 1 1.48 
Median 100 60.06 
Standard Deviation 26.21 34.58 
Range 91.26 97.42 
Minimum 8.74 2.58 
Maximum 100 100 
Total number of claims 56579 32660 
Number of patients 687 546 
Largest 100 100 
Smallest 8.74 2.58 
Confidence 
Level(95.0%) 
1.96 2.91 
 
The study population were covered with one of the following type of coverages during the study 
period: Temporary assistance for needy families (TANF), Medicaid Expansion, Supplemental 
security income Non-dual (SSI Non-Dual), Foster care. Eligibility criteria for each of the 
coverages is different and all of them provide low-cost healthcare coverage to Americans falling 
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under one or more of the following criteria: people with low income, children, foster care, 
families, pregnant women, mental health and substance use disorder, elderly or people with 
disabilities. Table 2. 18., shows that 279 members out of the total asthma patients were covered 
under TANF are control medication adherent and 142 members do not take their medication as 
prescribed. Out of 87 SSI non dual covered patients, 47 are control medication adherent and 40 
are non-adherent to control medication. 
Table 2. 18. MPR for Control and Rescue medication depending on the type of insurance. 
Coverage 
Control medication MPR(less than 
80) 
Control Medication MPR (greater 
than 80) 
TANF 142 279 
SSI non-dual 40 47 
Medicaid expansion 28 125 
Foster care 2 15 
CHIP 0 2 
Behavioral Health 1 6 
Total 213 474 
 
3.5.3 Multivariate logistic regression for hypothesis #1 
 
Factors associated with control medication adherence were analyzed using backward selection in 
multivariate logistic regression. In step 0: age, gender, income level, number of inpatient admits, 
number of emergency department visits, number of 30 and 90 day readmissions, case 
management status, and type of insurance coverage  (i.e., Temporary assistance for needy 
families (TANF), Medicaid Expansion, Supplemental security income Non-dual (SSI Non-Dual), 
Foster care) were entered into the model. After performing multivariate logistic regression the 
following variables were removed from the model (Table 2. 19.).  
 
 
 
From table 2. 20, it is clear that two types of insurance coverage TANF and SSI-nondual (p-
values=<0.0001) are significant at 0.05 level. Also even though age, male and 30-day 
readmissions were not significant at 0.05 level, they were still allowed into the model since their 
Table 2. 19. Summary of effects removed in backward elimination 
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coefficients’ directions are consistent with literature (i.e. females are more adherent to 
medication than males, older people are less adherent than younger population). Model fit 
statistics for the final model is shown in Table 2. 21. 
Table 2. 20. Analysis of maximum likelihood. 
 
Table 2. 21. Model fit statistics 
 
The equation for the final model is: 
Log (odds of control medication adherence) = 2.0672-0.0121*age-0.2456*male+0.3888*30 day 
readmissions-1.1399*TANF-1.5228*SSI-nondual 
Table 2. 22. Odds ratio for multivariate logistic regression for asthma patients (n=687). 
 
From Table 2. 22. 
(i) It can be seen that patients with TANF and SSI Non-dual coverages tend to be less 
adherent to control medication adherence than other coverages (odds of TANF being 
adherent is 0.320 times and SSI non dual is 0.218 times lesser than other insurance 
types and they are both significant at 0.05 level).  
(ii) Older patients are less adherent to medication than younger patients (Odds for an 
older patient being adherent is 0.988 times less the odds of younger patient [OR 
0.988, 95% CI (0.975-1.001)]) this result is not significant at 0.05 level.  
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(iii) Men are less adherent to control medication (Odds of male being adherent is 0.782 
times less than female being adherent) this result is not significant at 0.05 level.  
(iv) Patients with 30-day readmissions have higher control medication adherence 
compared to patients without readmissions (Odds for patients with 30-day 
readmissions being adherent are 1.475 times higher than the odds of patients without 
30-day readmissions) this result is not significant at 0.05 level.  
Table 2. 22. Testing of global null hypothesis for the multivariate logistic regression analysis. 
 
The overall logistic regression model was highly significant at the 5% significance level as 
indicated by the likelihood ratio, Wald and score tests of the global null hypothesis i.e., the 
model parameters are significant (Table 2. 22). 
Following is a table of Summary for the factors that were retained in the regression model after 
backward elimination. 
Table 2. 23. Summary for multiple logistic regression. 
 
3.5.4 T- Test case managed and non-case managed adherence for hypothesis #2 
In order to address H2, exploring if both control and rescue medication, will differ among case 
managed and non-cased managed patients, a t test was performed.  
 
First part in table 2. 24, displays the mean and the standard deviation, and confidence interval of 
the means of control medication adherence depending on whether the patient is a case managed 
or not. Table 2. 24, shows that the null hypothesis of equal means and equal variance is not 
rejected since the p-value is greater than 0.05 (p=0.1655). It can be concluded that control 
medication adherence will not differ among case managed and non-case managed patients (p-
value=0.1310, is greater than 0.05 significance level for pooled). 
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Table 2. 24. T-test for control medication adherence among (1=case managed and 0= non-case managed 
asthma patients)  
 
From table 2. 25. below, since p-value for the test of equality of variances (p-value=0.8936) is 
greater than 0.05, the variances are equal and therefore we look at the p-value for pooled section. 
It is 0.5424 (greater than 0.05). Therefore, adherence to rescue medication does not seem to 
differ among case managed and non-case managed patients. 
Table 2. 25. T-test for Rescue medication adherence (1=case managed and 0= non-case managed asthma 
patients)  
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3.5.5 Telephone interview: 
Out of the entire asthma population for the study (n=687), 41 patients are case managed. When 
contacted, only 4 of 41 case managed patients participated in the interview. Therefore, case 
managed asthma patients outside our main study population (n=687) were also contacted for the 
telephone interview. A total of 27 asthma patients (15 non-case managed and 12 case managed 
patients) participated in the telephone interview. Demographic, socioeconomic and clinical data 
of these patients, obtained from the interview questions are displayed in the table 2. 26. below. 
Mean age of this population was 22 years. There were equal number of African American and 
Caucasian patients in both case managed (6 Caucasian, 6 African American) and non-case 
managed groups (7 Caucasian, 7 African American and 1 not specified). Students were in 
majority among the two groups. About 75% patients in both groups were single and had 
comorbidities (chronic illnesses other than asthma). More than 80% patients had a primary care 
physician (PCP). 
Table 2. 26. Interview population (15 non case managed and 12 case managed) 
Variables Non case managed 
(n=15)  
Case managed 
(n=12) 
Age (Mean) 24 years 22 years 
Gender     
Male 3 (20%) 7 (58%) 
Female 12 (80%) 5 (42%) 
Asthma severity     
Mild  7 (46.6%) 5 (41.6%) 
Intermittent 3 (20%) 4 (33.3%) 
Severe 5 (33.3%) 3 (25%) 
Ethnicity     
African American  7 (46.6%) 6 (50%) 
Caucasian 7 (46.6%) 6 (50%) 
Will not specify 1 (6.6%) 0 
Employment status     
Unemployed 4 (26.6%) 4 (33.3%) 
Employed 3 (20%) 0 
Student 6 (40%) 7 (58%) 
Retired 1 (6.6%) 1 (8.3%) 
Does not apply 1 (6.6%) 0 
Education     
Elementary School 4 (26.6%) 4 (33.3%) 
Middle school 2 (13.3%) 2 (16.6%) 
High School Graduate 3 (20%) 2 (16.6%) 
College Graduate 3 (20%) 2 (16.6%) 
Drop out 2 (13.3%) 0 
Does not apply 1 (6.6%) 0 
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Variables 
(Cont’d) 
Non case managed 
(n=15) (Cont’d) 
Case managed 
(n=12) (Cont’d) 
No answer 0 2 (16.6%) 
Marital status     
Single 12 (80%) 9 (75%) 
Married 2 (13.3%) 1 (8.3%) 
Separated 0 1 (8.3%) 
Divorced 1 (6.6%) 0 
Widowed 0 1 (8.3%) 
Members in the house     
4 or less 9 (60%) 8 (66.6%) 
5 or more 6 (40%) 4 (33.3%) 
Comorbidities     
Yes 11 (73.3%) 9 (75%) 
No 4 (26.6%) 2 (16.6%) 
PCP     
Yes 13 (86.6%) 10 (83.3%) 
No 2 (13.3%) 2 (16.6%) 
 
Following table 2. 27. Shows the yes and no responses of case managed and non-case managed 
asthma patients for questions regarding their medications, physician and themselves.  
Table 2. 27. Interview questions and responses among non-case managed and case managed asthma 
patients (n=27). 
Interview questions Non case managed 
(n=15)  
Case managed (n=12)  
  Yes No Yes No 
Currently taking medications 11 
(73.3%) 
4 (26.6%) 10 (83.3%) 2 (16.6%) 
Control medication even without symptoms 6 (40%) 9 (60%) 5 (41.6%) 7 (58%) 
Physician related questions         
Taught you to recognize early signs of symptoms 12 (80%) 3 (20%) 10 (83.3%) 2 (16.6%) 
Have an asthma action plan 7 (46.6%) 8 (53.3%) 9 (75%) 3 (25%) 
Showed you how to use an inhaler 14 
(93.3%) 
1 (6.6%) 12 (100%) 0 
Patient related questions         
Take medications even during symptomless period 10 
(66.6%) 
5 (33.3%) 6 (50%) 6 (50%) 
Well informed about asthma  medication 12 (80%) 3 (20%) 11 (91.6%) 1 (8.3%) 
Side effects with medication 2 (13.3%) 13 
(86.6%) 
2 (16.6%) 10 
(83.3%) 
Medications not working 5 (33.3%) 10 
(66.6%) 
1 (8.3%) 11 
(91.6%) 
Do not need preventive treatment 6 (40%) 9 (60%) 4 (33.3%) 8 (66.6%) 
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Forgot to refill 3 (20%) 12 (80%) 5 (41.6%) 7 (58%) 
See different PCP every visit 5 (33.3%) 10 
(66.6%) 
1 (8.3%) 11 
(91.6%) 
Too many medicines 2 (13.3%) 13 
(86.6%) 
2 (16.6%) 10 
(83.3%) 
Skipped medication due to cost 4 (26.6%) 11 
(73.3%) 
3 (25%) 9 (75%) 
Lack of transportation  2 (13.3%) 13 
(86.6%) 
1 (8.3%) 11 
(91.6%) 
Anybody in the house smoke or drink 1 (6.6%) 14 
(93.3%) 
5 (41.6%) 7 (58%) 
Family support 14 
(93.3%) 
1 (6.6%) 12 (100%) 0 
 
Although responses for most of the questions in table 2. 27, above look similar among the two 
groups. By inspection, from table 2. 28. below, the average MPR for control and rescue 
medication adherence seem a little higher among non-case managed compared to case managed 
asthma patients of the interview population.   
Table 2. 28. Average control and rescue medication adherence (15 non case managed and 12 case 
managed) 
Variable Non case managed  Case managed 
Average Control medication 
adherence 
30.4 22.83 
Average Rescue medication 
adherence 
57.73 16.92 
 
A t-test was performed for three questions from the phone interview list, including 1) Do you 
have an asthma action plan?, 2) Do you forget to refill your control medication?, and 3) Do you 
see different Primary care physician every visit?. The purpose of this test was to find any 
significant difference among the two groups (case managed and non-case managed). Significant 
difference was found for the third question- do you see different PCP every visit. Results showed 
a significant difference among the responses of case managed and non-case managed asthma 
patients (p-value 0.053). Results of the t-test are attached in Appendix E. 
3.6 Discussion  
From the literature review, it can be concluded that medication adherence is of utmost 
importance among patients with chronic illness. Although several guidelines have been laid out, 
patients with chronic illnesses tend to derail from taking medications as prescribed. Average 
adherence to control medication (measured by electronic devices) was reported to be 50% to 
77% by previous studies (Coutts et.al, 1992; Milgrom et.al, 1996; Burgess, 2011). This study 
found an average control medication adherence of 82.3% (SD=26.2), while rescue medication 
adherence was only 59% (SD=34.6). Rescue medications are only used as needed i.e., in case of 
asthma attacks for quick relief. Therefore, focus was placed on control medication adherence. 
This study identified five variables that may help explain control medication adherence among 
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asthma patients. Two demographic variables, age and gender, one clinical variable, 30 day 
readmissions to the hospital, and two types of Medicaid insurance (TANF and SSI Non dual) 
remained in the model. Furthermore, only the two types of insurance coverage, TANF (p-value 
=<0.0001) and SSI- non dual (p-value =<0.0001) were significant at 0.05 level. 
Age and gender are the two demographic factors that have been studied widely in the literature in 
association with medication adherence. Age has been found to affect adherence by some 
researchers (Jonasson, 1999; Strunk, 2002). Strunk et al. found that for every 2 year increase in 
age a child was more likely to be non-adherent to asthma medication. Similar results were found 
by another study, adolescents might be at increased risk of non-adherence (Kyngas, 1999). 
Conversely, some studies reported that older adults showed better adherence than younger adults 
(Tebbi, 1993). In the present study, adherence among older patients although not significant, 
found to be less than younger patients [OR=0.988, 95% CI (0.975-1.001)]. The difference in age 
might be a risk factor for several reasons such as forgetfulness, unwillingness to take medication 
daily, and comorbidities, etc. Number of female asthma patients (n=384) were slightly higher 
than males (n=303) in the present study females were more adherent than males. A study by 
Lindberg et. al., on medication compliance among asthma patients found similar results i.e., age 
and female gender were associated with medication taking behavior (Lindberg, Ekstrom, Moller, 
& Ahlner, 2001). 
Medication adherence has been reported as a predictor of 30-day hospital readmissions in many 
studies (Rosen et al., 2017). Therefore, even though non-significant, 30 day readmissions was 
considered in the study since it was consistent with the literature with odds ratio [OR=1.475, 
95% CI (0.841-2.589)]. Patients can be admitted or readmitted to the hospital for multiple 
reasons ranging from asthma attack, exacerbation or decline in health. These patients are most 
definitely given asthma medications upon discharge from the hospital facility. This could be the 
reason behind association between patients with 30-day readmissions and medication adherence. 
Insurance coverage: TANF and SSI non dual were two types of coverage found to be significant 
predictors of control medication adherence. People with TANF and SSI non dual are less 
adherent to control medication compared to other types of insurance coverages. TANF stands for 
temporary assistance for needy families and SSI non dual stands for supplemental security 
income (SSI) non dual. Although TANF supports families with one or more members with 
disability, eligibility for TANF is determined by income (Nadel, 2003; Ziliak, 2004). Majority of 
the asthma study population was covered under TANF (n=421) and SSI non dual coverages 
(n=87). A study to predict risk factors for cost-related medication non-adherence among older 
diabetes reported that factors such as out-of-pocket payments for medications and insurance 
status contribute to higher risk of medication non-adherence (Zhang et. al, 2014). 
Comparing the medication adherence for case and non-case managed patient, results showed that 
there was 95% chances that control medication adherence for non-case managed patient would 
fall between 80.18 and 84.26. Similarly, there was 95% chances that control medication 
adherence for case managed patient would fall between 77.28 and 84.51(Tables 8.1 and 8.2). 
Since the upper bound for both groups could be greater than or equal to 80 (the threshold for 
medication adherence), these patients will be considered adherent.  The t-test concluded that 
control medication adherence does not significantly differ among case managed and non- case 
managed patients. Similar results for rescue medication adherence were documented from this 
study. Although the study hypothesized that case managed population would have better 
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medication adherence than non-case managed asthma patients, the results looked otherwise. One 
possible reason could be a small sample size and proportion of patient’s case managed versus 
non case managed. The difference in number of case managed (n=41) and number of non-case 
managed patients for control medication (n=646), and difference in the number of case managed 
(n=35) and non-case managed asthma patients (n=511) for patients taking rescue medications. 
The telephone interviews were conducted to collect responses on various questions related to 
demographics, socioeconomic status, medications, physicians and specific questions pointing at 
factors for non-adherence to asthma medications. For the question, “Did you take asthma 
medication without suffering an attack?” 6 out of 15 (40%) of the non-case managed and 5 out of 
12 (41.6%) of the non-case managed patients reported yes and a similar question (take control 
medications even during symptomless period) later on in the interview yielded different 
responses i.e. 66.6% non-case managed and 50% of case managed patients said yes. When 
claims data was used to calculate average control and rescue medication adherence among these 
patients. The average MPR values were very low (in table 9.3). 4 out of the 5 non case managed 
patients that responded yes for “skipped or stopped taking medication because they were not 
working” were African Americans and one was Caucasian. 33% of non-case managed and 8% of 
case managed patients reported that they see different physician every time even though they had 
primary care physician’s assigned to them. About 25% of both groups reported that they skipped 
medications due to cost of medication, While 20 % of non-case managed and 41% of case 
managed patients reported that they forgot to refill their medications on time. Since the sample 
size of the telephone interview respondents is small, it is hard to conclude strongly about the 
factors that might affect medication adherence, even though some kind of trend is seen in the 
responses. To rectify this, a larger sample group with a face-to-face or a questionnaire to be filled 
via email might get better details and more number of respondents.  
3.6.1 Ethical considerations 
Data will be de-identified and necessary steps such as HIPAA training will be taken to honor the 
privacy of patients and their data. Protection of participants will be ensured by taking approval 
from Institutional Review Board and submitting needed consent documents. Patients were free to 
decline participation in the survey methods. The principles of ethical research practices such as 
confidentiality and anonymity will be followed.    
3.6.2 Limitations 
Limitations of using pharmacy claims data is assumption that a prescription filled is a 
prescription consumed. Pharmacy claims data may not reflect stopping medication due to 
physician’s orders or change in patient schedules. Sample was not be divided upon the drug 
class. Medication possession ratio used to calculate medication adherence for this population has 
a few short comings as it only helps calculate consistency and not persistency. 
3.6.3 Summary and Conclusion 
In conclusion, the two types of insurance coverage (TANF and SSI-non dual) were the only 
significant predictors of control medication adherence among the factors considered in this 
study. Also, the t-test of the asthma population (n=687) results showed that control and rescue 
medication adherence is not significantly different among case managed and non-case managed 
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asthma patients. The sample of 687 asthma patients and also the respondents (n=27) of telephone 
interview for this study did not provide enough basis to propose an effective selection criteria for 
interventions (i.e. case management type of intervention) in order to improve control medication 
adherence.  
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FINAL CONCLUSION 
The asthma population for this study consisted of patients with Medicaid insurance coverage. 
Medicaid insurance in principal covers members with low income conditions. Results found that 
control medication adherence has no relationship with any type of hospital visit, patients with 
rescue medication adherence tend to have lower emergency visits and inpatient admissions. 
Patients with more than 4 office visits had better rescue medication adherence but not control 
medication adherence. This goes to explain that people might not follow their doctor’s orders on 
control medication but are knowledgeable in the use of rescue medication. Even though this 
seems like a good practice, it is not since use of rescue medication should be limited and control 
medications should be taken as prescribed by the doctor to avoid exacerbations. Further, patients 
with TANF and SSI-non dual coverages tend to be less adherent to control medication compared 
to other coverages. Also, males and low income patients were found to have emergency 
department visits and older lower income patients have more 30 day-readmissions. Even though 
the results from the analysis and responses for the interview questions was not enough 
information to propose a selection criteria to improve control medication adherence, they 
provided clear picture on what needs to be done. Asthma patients need to be educated on the use 
of control medication, rather than wait until they have an asthma attack and take rescue 
medication for quick relief. Male, older and low income patients should be further studied to 
reduce hospital visits and improve medication adherence. It was also found that control and 
rescue medication adherence was not significantly different among case managed and non-case 
managed patients. 
Future Research 
In order to identify hospital utilizations in connection with medication adherence, it would be 
advisable for future researchers to consider a larger sample with more variables such as patient’s 
race/ ethnicity, individual income, medication cost for each claim, employment status, education, 
hospital discharge instructions, physician and patient relation, classification of office visits 
(scheduled or unscheduled) and detailed analysis of medications (classification, drug classes, 
etc.). Above mentioned variables when analyzed similar to this study might lead to predicting 
and improving medication adherence for asthmatic patients. 
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APPENDIX A: ICD 9 & ICD 10 CODES 
 
 
ICD 9 codes 
 
 
ICD 10 codes 
J45 Asthma 
J45.2 Mild Intermittent Asthma 
J45.20 Mild Intermittent Asthma, Uncomplicated 
J45.21 Mild Intermittent Asthma with (Acute) Exacerbation 
J45.22 Mild Intermittent Asthma with Status Asthmaticus 
J45.3 Mild Persistent Asthma 
J45.30 Mild Persistent Asthma, Uncomplicated 
J45.31 Mild Persistent Asthma with (Acute) Exacerbation 
J45.32 Mild Persistent Asthma with Status Asthmaticus 
J45.4 Moderate Persistent Asthma 
J45.40 Moderate Persistent Asthma, Uncomplicated 
J45.41 Moderate Persistent Asthma with (Acute) Exacerbation 
J45.42 Moderate Persistent Asthma with Status Asthmaticus 
J45.5 Servere Persistent Asthma 
J45.50 Servere Persistent Asthma, Uncomplicated 
J45.51 Servere Persistent Asthma with (Acute) Exacerbation 
J45.52 Servere Persistent Asthma with Status Asthmaticus 
J45.9 Other and Unspecified Asthma 
J45.90 Unspecified Asthma 
J45.901 Unspecified Asthma with (Acute) Exacerbation 
J45.902 Unspecified Asthma with Status Asthmaticus 
J45.909 Unspecified Asthma, Uncomplicated 
J45.99 Other Asthma 
J45.990 Exercise Induced Bronchospasm 
J45.991 Cough Variant Asthma 
J45.998 Other Asthma 
493 Asthma 
493 Extrinsic Asthma 
493.1 Intrinsic Asthma 
493.2 
Chronic Obstructive 
Asthma 
493.8 Other Forms of Asthma 
493.81 
Exercise Induced 
Bronchospasm 
493.82 Cough Variant Asthma 
493.9 Unspecified Asthma 
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APPENDIX B: NON-ASTHMATIC GROUP TABLES 
Non-asthmatic group diagnosis 
Diagnosis 
Count 
of 
Member 
ID 
Count of Actual Admission Date 
ABDOMINAL PAIN, UNSPECIFIED SITE 1 1 
AC CHRN COMB SYSTOLIC AND DIASTOL CHF 1 1 
ACUT MI OTH INF WALL INIT EPIS CARE 1 1 
ACUT MI SUBNDOCRDL INFARCT INIT EOC 1 1 
ACUTE CHRON SYSTOLIC HEART FAILURE 1 1 
ACUTE CHRONIC RESP FAIL W/HYPOXIA 1 1 
ACUTE EMBO THROMBOS RT FEMORAL VEIN 1 1 
ACUTE KIDNEY FAILURE UNSPECIFIED 2 2 
AGRANULOCYTOSIS SEC TO CANCER CHEMO 1 1 
ALCOHOL USE UNS W/UNS ALC-INDUC D/O 1 1 
ALCOHOLIC GASTRITIS WITH HEMORRHAGE 1 1 
ALCOHOLIC HEPATIC FAILURE W/O COMA 2 2 
ALTERED MENTAL STATUS UNSPECIFIED 2 2 
ASPERGILLOSIS 2 2 
ASPERGILLOSIS UNSPECIFIED 1 1 
ATHSC NATV ART EXT REST PAIN BIL 1 1 
ATHSC NATV ART EXT W/GANGREN LT LEG 1 1 
BENIGN NEOPLASM COLON UNSPECIFIED 1 1 
BENIGN NEOPLASM OF RIGHT OVARY 1 1 
BILIARY ACUTE PANCREATITIS 1 1 
BIPOLAR CURR DEPRESS SEV W/O PSYCH 1 1 
BIPOLAR CURR DEPRESS SEV W/PSYCH 1 1 
BIPOLAR CURR DEPRESSED MILD/MOD UNS 2 2 
BIPOLAR DISORDER UNSPECIFIED 1 1 
BIPOLAR II DISORDER 1 1 
CELLULITIS AND ABSCESS OF MOUTH 1 1 
CELLULITIS&ABSC UPPER ARM&FOREARM 1 1 
CELLULITIS&ABSCESS LEG EXCEPT FOOT 1 1 
CELLULITIS&ABSCESS OTHER SPEC SITE 1 1 
CEREB INFARCT EMBO RT ANT CEREB ART 1 1 
CEREBRAL INFARCTION UNSPECIFIED 1 1 
CHF UNSPECIFIED 1 1 
CLOSED FRACTURE OF SHAFT OF HUMERUS 1 1 
COPD WITH ACUTE EXACERBATION 2 2 
CORD AROUND NECK-COMPRS DEL 1 1 
CRITICAL ILLNESS MYOPATHY 1 1 
CUTANEOUS ABSCESS LEFT UPPER LIMB 1 1 
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CUTANEOUS ABSCESS OF NECK 1 1 
DECR FETAL MOVEMENTS UNS TRI NA/UNS 1 1 
DISORDER OF BRAIN UNSPECIFIED 1 1 
DISPLACEMENT INSULIN PUMP INITIAL 1 1 
DISPLCMT LUMBAR DISC W/O MYELOPATHY 1 1 
DVTRCLI LG INT NO PERF/ABSC W/O BL 1 1 
EMBOLISM THROMBOSIS ART UP EXTREM 1 1 
EPILEPSY UNS NOT INTRACT W/O SE 1 1 
ESOPHAGEAL REFLUX 1 1 
FIRST DEG PERINEAL LAC DUR DELIV 1 1 
FX UNS PRT NCK RT FEM INIT CLOS 1 1 
HB-SS DISEASE WITH CRISIS 7 7 
HB-SS DISEASE WITH CRISIS UNS 12 12 
HEMIPLG FLW CEREB INFARCT LT N-DOM 1 1 
HEMPLG OTH NTRM INTRCRN HEM L N-DOM 1 1 
IMMUNE THROMBOCYTOPENIC PURPURA 2 2 
INF&INFLAM REACT INT ORTH DEVICE 1 1 
INTEST ADHES W/OBST POSTPROC-INFECT 1 1 
INTESTINAL INF DUE OTH ORGANISM NEC 1 1 
LABOR AND DEL COMP FETAL STRESS UNS 1 1 
LAC NO FB LT F WALL THOR NO PEN INT 1 1 
MAJ DEPRESS D/O RECURRENT MOD 1 1 
MAJ DEPRESS D/O SINGLE EPIS UNS 4 4 
MAJ DEPRESS RECURR SEV W/O PSYCH 4 4 
MAJ DEPRESS RECURR SEV W/PSYCH SX 1 1 
MAJOR DEPRESSIVE D/O RECURRENT UNS 2 2 
MISSED ABORTION 1 1 
MORBID SEV OBESITY ALVEOLR HYPOVENT 1 1 
MULTIPLE SCLEROSIS 1 1 
MYCOPLASMA INFECTION UNSPECIFIED 1 1 
NONINFECTIVE GE AND COLITIS UNS 1 1 
NON-ST ELEVATION MYOCARDIAL INFARCT 1 1 
NONTRAUM IC HEMORR HEMISPH SUBCORT 1 1 
NORMAL DELIVERY 2 2 
OPEN WND FOREHEAD W/O MENTION COMP 1 1 
OPIOID DEPENDENCE WITH WITHDRAWAL 1 1 
OTH COMPS DUE INTRL JOINT PROSTH 1 1 
OTH CURRENT MATERNAL CCE ANTEPARTUM 1 1 
OTH CURRENT MATERNAL CCE W/DELIVERY 2 2 
OTH MECH COMP INSULIN PUMP INITIAL 1 1 
OTH SPEC ABNORMAL UTERINE VAG BLEED 1 1 
OTH SPEC DIAB KETOACIDOSIS NO COMA 1 1 
OTHER CHEST PAIN 1 1 
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OTHER CONVULSIONS 1 1 
OTHER GRAM-NEGATIVE SEPSIS 2 2 
OTHER NEUTROPENIA 1 1 
OTHER POSTOPERATIVE INFECTION NEC 1 1 
OTHER SPEC REHABILITATION PROCEDURE 1 1 
OTHER SPECIFIED SEPSIS 1 1 
PARALYTIC ILEUS 1 1 
PARANOID SCHIZOPHRENIA 6 6 
PERIAPICAL ABSCESS WITHOUT SINUS 1 1 
PERIPHERAL VASCULAR DISEASE UNS 1 1 
PNEUMOCOCCAL PNEUMONIA 1 1 
PNEUMONIA UNSPECIFIED ORGANISM 5 5 
PNEUMONIA, ORGANISM UNSPECIFIED 1 1 
POISN OTH RX MEDS BIO SUBS ACC INIT 1 1 
POISON OTH OPIOIDS ACC INITIAL ENC 1 1 
POISONING BY OPIUM , UNSPECIFIED 1 1 
POST-TERM PREGNANCY 1 1 
PRE-EXISTING DM TYPE 2 PREG 3RD TRI 1 1 
PREMATURE RUPTURE MEMB PG DELIV 1 1 
PREV C/S DEL DEL W/WO ANTPRTM COND 3 3 
RADICULOPATHY LUMBAR REGION 1 1 
SALPINGITIS AND OOPHORITIS UNS 1 1 
SCHIZOAFFECTIVE D/O BIPOLAR TYPE 2 2 
SCHIZOPHRENIA UNSPECIFIED 2 2 
SEPSIS UNSPECIFIED ORGANISM 1 1 
SEVERE PRE-ECLAMPSIA, WITH DELIVERY 1 1 
SLTR-HARIS II FX LW LT FEM CLO 1 1 
STREP B CARR STATE COMP CHILDBIRTH 1 1 
SYNOVIAL CYST OF POPLITEAL SPACE 1 1 
SYSTEMIC LUPUS ERYTHEMATOSUS 1 1 
THROMB VASC PROSTH DEVC GRAFT INIT 1 1 
TYPE 2 DM W/FOOT ULCER 2 2 
UNS DISLOC RT ULNOHUMERAL JNT INIT 1 1 
UNS FX SHFT LT RADIUS INIT OPN I/II 1 1 
UNS NONINF GASTROENTERIT&COLITIS 1 1 
UNSPEC HEMORRHAGE GI TRACT 1 1 
UNSPEC HTN HEART DISEASE W/HF 2 2 
UNSPECIFIED ABDOMINAL PAIN 1 1 
UNSPECIFIED ACUTE APPENDICITIS 1 1 
UNSPECIFIED ANEMIA 1 1 
UNSPECIFIED CONSTIPATION 1 1 
UNSPECIFIED ESSENTIAL HYPERTENSION 1 1 
UNSPECIFIED INTESTINAL OBSTRUCTION 1 1 
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UNSPECIFIED SEPTICEMIA 2 2 
UNSPECIFIED URETHRAL STRICTURE 1 1 
UTI SITE NOT SPECIFIED 3 3 
VENTRICULAR FIBRILLATION 1 1 
Grand Total 179 179 
 
Cluster history of non-asthmatic group 
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Appendix C: SCATETRPLOT FOR CORRELATION ANALYSIS 
 
Scatterplot for correlation between emergency department visits, inpatient admissions, 30 day 
readmissions, 90 day readmissions and control medication adherence 
 
 
 
 
 
 
 
 
 
 
76 
 
Scatterplot for correlation between emergency department visits, inpatient admissions, 30 day 
readmissions, 90 day readmissions and rescue medication adherence 
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APPENDIX D: REGRESSION ANALYSIS 
 
Correlation matrix between the independent variable 
 
 
 
 
 
     
 
 
Scatterplot of the correlation matrix 
 
Scatter Plot Matrix
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Control medication with age, gender and income. 
  
Emergency visits with age, gender and income 
 
 
Inpatient Admits with age, gender and income 
 
30 day readmission with age, gender and income 
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90 day readmission with age, gender and income 
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APPENDIX E: TELEPHONE INTERVIEW 
 
Telephone interview Procedure and Questions 
Plan: 
 2 pilot Interviews to track duration 
 Reduce or rephrase questions depending on this 
 Sample size for interviews: 60 (30 case managed/ 30 without it) 
Case manager randomly picks members from asthma population. Introduces herself. 
1. Are you (the person we intended to call)? May I confirm your/ your child’s age and 
gender? 
2. Have you ever been diagnosed for asthma? Yes, continue. If not end the call 
3. What category of asthma do you have? (mild/intermittent/severe) 
4. Race/ ethnicity 
5. Employment status/ education 
6. Marital status/ family members 
7. Comorbidities? 
8. Do you have a PCP? 
9. Are you case managed or do you take any such services provided by the insurance 
company? 
10. (IF YES for q.9) Rate case management or disease management services provided to you 
by the insurance company 
11. Do you know about the transportation facility provided by the insurance company? 
12. During the past three months how many asthma attacks have you had? And how long did 
they last (dash minutes, dash hours, dash days, dash weeks)? 
Medication related 
13. Are you currently taking any medications? What are they? How often? 
14. In the past 3 months have you taken prescription asthma medicine? 
15. In the past 3 months did you take asthma medication when you did not have an asthma 
attack? Or on regular schedule as by the doctor 
Physician related 
16. Has a doctor ever taught you to recognize early signs of symptoms of an asthma episode? 
What to do during an asthma episode or prevent an attack? 
17. Do you have an asthma action plan? How long ago did you get it? 
18. Did a health professional show you how to use an inhaler?  
 
Patient related 
19. Let me know if the following are reasons for non-adherence? 
 Take control medication even during symptomless period? 
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 How well informed do you feel about your health and medication (asthma 
education/ Uncertain how to use medication/ Uncertain when to use medication) 
 Side effects with asthma medication 
 Rx wasn’t working/ Skipped or stopped taking a medicine because you didn't 
think it was working? 
  Don’t need the ICS/ Does not need preventive treatment 
 Forgetting to take medication/ did not refill on time/ ran out of medication/ not 
had medicine with you when it was time to take it? 
 Stopped taking medication 
 See different provider each visit (PCP) 
 Number of prescription medications (Complicated regimen/ Taking medicines 
more than once a day is inconvenient.) 
 Skipped, stopped, not refilled, or taken less medicine because of the cost? / 
coverage for prescription medication 
 Lack of transportation 
 Do you or anybody in your home smoke/ drink alcohol? 
 Family support 
 
t-test results for: 
 
Asthma action plan 
 
Method Variances DF t Value Pr > |t| 
Pooled Equal 25 1.5 0.1473 
Satterthwaite Unequal 24.754 1.52 0.1416 
Cochran Unequal . 1.52 0.1541 
 
    
Equality of Variances 
Method Num DF Den DF F Value Pr > F 
Folded F 14 11 1.3 0.6671 
 
Forgot to refill medication 
 
Method Variances DF t Value Pr > |t| 
Pooled Equal 25 1.21 0.2364 
Satterthwaite Unequal 20.924 1.18 0.2499 
Cochran Unequal . 1.18 0.2599 
 
    
Equality of Variances 
Method Num DF Den DF F Value Pr > F 
Folded F 11 14 1.55 0.4373 
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Primary casre phyician 
 
Method Variances DF t Value Pr > |t| 
Pooled Equal 25 1.92 0.0659 
Satterthwaite Unequal 22.865 2.04 0.053 
Cochran Unequal . 2.04 0.0622 
 
    
Equality of Variances 
Method Num DF Den DF F Value Pr > F 
Folded F 14 11 3.09 0.0672 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
83 
 
APPENDIX F: ASTHMA PROCEDURES & CODES 
 
Asthma procedure codes and description 
 
Codes Asthma procedure code description 
94010 Spirometry: FVC, VC with or without MVV 
94011 Up to 2 years old Spirometry 
94012 2 years Spirometry w/dilator 
94013 2 years lung volumes 
94014 Patient recoded spirometry 
94015 Patient recorded spirometry 
94016 Review patient spirometry 
94060 Evaluation of wheezing 
94070 Evaluation of wheezing 
94150 Vital capacity requires hook up spirometry 
94375 Respiratory flow volume loop 
94620 Pulmonary stress testing 
94640 Pressurized or non-pressurized inhalation treatment  
94664 Demonstration and/or evaluation of patient utilization of  nebulizer, metered dose  
94760 Noninvasive ear or pulse oximetry for oxygen saturation; single determination 
94761 Noninvasive ear or pulse oximetry for oxygen saturation; multiple determination 
94762 Noninvasive ear or pulse oximetry by continuous overnight monitoring 
A4614 Peak expiratory flow rate meter handheld 
J7611 Albuterol, inhalation solutions, administered through DME, concentrated form, 1mg 
J7612 
Levalbuterol, inhalation solution, administered through DME, concentrated form, 
0.5mg 
J7613 Albuterol, inhalation solution, administered through DME, unit dose, 1mg 
J7614 Xopenex: Levalbuterol, inhalation solution, administered through DME 
J7626 Budesonide inhalation solution non compounded up to 0.5 mg 
J7627 Budesonide inhalation solution compounded up to 0.5 mg 
J7644 Atrovent: Ipratropium bromide, inhalation solution administered through DME 
J7645 Ipratropium bromide inhalation solution 
S8096 Portable peak flow meter 
S8097 Asthma Kit 
S8110 Peak expiratory flow rate (physician services) 
S9441 Asthma education 
J7620 Albuterol all formulations inhalation 
J2357 Omalizunab 
J2810 Theophilline 
J7609 Albuterol all formulations inhalation 
J7610 Albuterol all formulations inhalation 
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APPENDIX G: IRB APPROVAL  
 
IRB Approval letter 
 
ACTION ON PROTOCOL APPROVAL REQUEST 
TO: Isabelina Nahmens 
Mechanical and Industrial Engineering 
FROM: Dennis Landin 
Chair, Institutional Review Board 
DATE: November 29, 2016 
  RE: IRB# 3722 
Institutional Review Board Dr. Dennis Landin, Chair 130 David Boyd Hall Baton Rouge, LA 70803 P: 
225.578.8692 
F: 225.578.5983 
irb@lsu.edu | lsu.edu/irb  
TITLE: Evaluating Asthma Care from Hospital to Home to prevent Hospital Readmissions 
New Protocol/Modification/Continuation:  New Protocol 
Review type: Full Expedited  X Review date:  6/15/2016 
Risk Factor: Minimal  X Uncertain Greater Than Minimal_   
Approved  X Disapproved   
Approval Date: 11/29/2016     Approval Expiration Date: 11/28/2017 
Re-review frequency: (annual unless otherwise stated) 
Number of subjects approved: N/A 
LSU Proposal Number (if applicable): 
Protocol Matches Scope of Work in Grant proposal: (if applicable) 
By: Dennis Landin, Chairman    
PRINCIPAL INVESTIGATOR: PLEASE READ THE FOLLOWING – 
Continuing approval is CONDITIONAL on: 
Adherence to the approved protocol, familiarity with, and adherence to the ethical standards of the 
Belmont Report, and LSU's Assurance of Compliance with DHHS regulations for the protection of 
human subjects* 
Prior approval of a change in protocol, including revision of the consent documents or an increase in the 
number of subjects over that approved. 
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Obtaining renewed approval (or submittal of a termination report), prior to the approval expiration date, 
upon request by the IRB office (irrespective of when the project actually begins); notification of project 
termination. 
1. Retention of documentation of informed consent and study records for at least 3 years after the study ends. 
2. Continuing attention to the physical and psychological well-being and informed consent of the individual 
participants, including notification of new information that might affect consent. 
3. A prompt report to the IRB of any adverse event affecting a participant potentially arising from the study. 
4. Notification of the IRB of a serious compliance failure. 
5. SPECIAL NOTE:  When emailing more than one recipient, make sure you use bcc. 
 
*All investigators and support staff have access to copies of the Belmont Report, LSU's Assurance with DHHS, 
DHHS (45 CFR 46) and FDA regulations governing use of human subjects, and other relevant documents 
in print in this office or on our World Wide Web site at http://www.lsu.edu/irb 
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